NAME: Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil)

SPONSOR: Identi Pharmaceuticals Inc.

APPROVAL DATE: October 17, 2011
CONTENTS

Reviews / Information Included in this Review

<table>
<thead>
<tr>
<th>Reviews / Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Tentative Approval Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Labeling Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Medical Review</td>
<td></td>
</tr>
<tr>
<td>Chemistry Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Bioequivalence Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Statistical Review</td>
<td></td>
</tr>
<tr>
<td>Microbiology Reviews</td>
<td></td>
</tr>
<tr>
<td>Administrative &amp; Correspondence Documents</td>
<td>X</td>
</tr>
</tbody>
</table>
Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated November 9, 2010, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil).

Reference is also made to your amendments dated December 29, 2010; January 10, January 13, May 12, August 22, September 29, and October 7, 2011.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil) to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug product (RLD), Derma-Smoothe/FS Topical Oil, 0.01% (Scalp Oil), of Hill Dermaceuticals Inc.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs

Reference ID: 3030042
should be advised of any change in the marketing status of this
drug.

Promotional materials may be submitted to FDA for comment prior
to publication or dissemination. Please note that these
submissions are voluntary. If you desire comments on proposed
launch promotional materials with respect to compliance with
applicable regulatory requirements, we recommend you submit, in
draft or mock-up form, two copies of both the promotional
materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires
that all promotional materials be submitted to the Division of
Drug Marketing, Advertising, and Communications with a completed
Form FDA 2253 at the time of their initial use.

As soon as possible, but no later than 14 days from the date of
this letter, submit, using the FDA automated drug registration
and listing system (eLIST), the content of labeling [21 CFR
314.50(l)] in structured product labeling (SPL) format, as
described at
http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLab
eling/default.htm, that is identical in content to the approved
labeling (including the package insert, and any patient package
insert and/or Medication Guide that may be required). Information
on submitting SPL files using eLIST may be found in the guidance
for industry titled "SPL Standard for Content of Labeling
Technical Qs and As" at
http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInf
ormation/Guidances/U CM072392.pdf. The SPL will be accessible via
publicly available labeling repositories.

Sincerely yours,

{See appended electronic signature page}

Keith Webber, Ph.D.
Deputy Director
Office of Pharmaceutical Science
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L WEST
10/17/2011
Deputy Director, Office of Generic Drugs for Keith Webber, Ph.D.
APPLICATION NUMBER:
ANDA 201759

LABELING
Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)

For Topical Use Only.
Not for Oral, Ophthalmic, or Intranasal Use

DESCRIPTION
Fluocinolone Acetonide 0.01% Topical Oil contains fluocinolone acetonide (6α, 11β, 16a)-6x-difluoro-11β,16-dihydroxy-16,17-(1-methylvinylidene)estradiol (progesterone 1,4-diene-3,20-dione, cyclopentane-1,2,4-trione, 6-oxo-1,2,4-triazoline-3,5-dione, cyclic 16,17 acetal with acetone), a synthetic corticosteroid for topical use. As with all corticosteroids, this preparation is for external use only and is flammable. This product is marketed as Fluocinolone Acetonide 0.01% Topical Oil for use as body oil for atopic dermatitis in adults and for minor skin irritation and inflammation due to a wide variety of causes in children over 2 years of age. It has been shown to be effective for the treatment of atopic dermatitis in children aged 7 to 12 years. In adults, Fluocinolone Acetonide 0.01% Topical Oil is also used in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing. Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing.

Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

information for Patients: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing.

Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

information for Patients: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing.

Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

information for Patients: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing.

Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

information for Patients: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing.

Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

information for Patients: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing.

Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

information for Patients: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing.

Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

information for Patients: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing.

Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

information for Patients: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper plastic pants may constitute occlusive dressing.
for 4 weeks to the face in children (2 to 12 years) with moderate to severe atopic dermatitis (see Table of Incidence of Adverse Events).

Incidence of Adverse Events (%)

<table>
<thead>
<tr>
<th>N=58</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse Event (AE)*</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>TEENAGEACNE</td>
</tr>
<tr>
<td>Erythema</td>
</tr>
<tr>
<td>Itching</td>
</tr>
<tr>
<td>Irritation</td>
</tr>
<tr>
<td>Numbness</td>
</tr>
<tr>
<td>Hypopigmentation</td>
</tr>
<tr>
<td>Itchy skin</td>
</tr>
<tr>
<td>Secondary atopic dermatitis</td>
</tr>
<tr>
<td>Papules and pustules</td>
</tr>
<tr>
<td>Keratitis plans</td>
</tr>
<tr>
<td>Folliculitis</td>
</tr>
<tr>
<td>Facial herpes simplex</td>
</tr>
<tr>
<td>Acneiform eruption</td>
</tr>
<tr>
<td>Ear infection</td>
</tr>
</tbody>
</table>

*The number of individual adverse events reported does not necessarily reflect the number of individual subjects, since one subject could have multiple reporting of an adverse event.

**End of Treatment

***Four Weeks Post Treatment

OVERDOSE
Topically applied Fluocinolone Acetonide 0.01% Topical Oil can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

DOSAGE AND ADMINISTRATION
Fluocinolone Acetonide 0.01% Topical Oil for scalp psoriasis in adults (Scalp Oil):
For the treatment of scalp psoriasis, wet or dampen hair and scalp thoroughly. Apply a thin film of Fluocinolone Acetonide 0.01% Topical Oil on the scalp, massage well and cover scalp with the supplied shower cap. Leave on overnight, or for a minimum of 4 hours before washing off. Wash hair with regular shampoo and rinse thoroughly.

HOW SUPPLIED
Fluocinolone Acetonide 0.01% Topical Oil is supplied in a 4 fluid ounce bottle with a net content of 118.28 mL. It is labeled as Scalp Oil (NDC 65162-703-86). Scalp Oil is supplied with 2 shower caps.

Keep tightly closed. Store upright at 25° C (68 to 77° F); excursions permitted to 15°-30° C (59°-86°F) [see USP Controlled Room Temperature].

CAUTION: Rx only

MANUFACTURED BY:
Amneal Pharmaceuticals
Branchburg, NJ 08876

DISTRIBUTED BY:
Amneal Pharmaceuticals
Glasgow, KY 42141

Rev: 05-2011
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 201759

LABELING REVIEWS
APPROVAL SUMMARY #1
REVIEWS OF PROFESSIONAL LABELING
DIVISION OF LABELING AND PROGRAM SUPPORT
LABELING REVIEW BRANCH

ANDA Number: 201759
Date of Submission: October 7, 2011
Applicant’s Name: Identi Pharmaceuticals, LLC.
Established Name: Fluocinolone Acetonide Oil, 0.01% (Scalp Oil)

REMS required? NO
MedGuides and/or PPIs (505-1(e)) □ Yes □ No
Communication plan (505-1(e)) □ Yes □ No
Elements to assure safe use (ETASU) (505-1(f)(3)) □ Yes □ No
Implementation system if certain ETASU (505-1(f)(4)) □ Yes □ No
Timetable for assessment (505-1(d)) □ Yes □ No

ANDA REMS acceptable? □ Yes □ No □ n/a

APPROVAL SUMMARY (List the package size, strength(s), and date of submission for approval):

Do you have Final Printed Labels and Labeling? Yes

1. CONTAINER (4 oz bottle) - Satisfactory in Final Print as of October 7, 2011 electronic submission.
2. CARTON (4 oz bottle) – Satisfactory in Final Print as of October 7, 2011 electronic submission.
3. PACKAGE INSERT – Satisfactory in Final Print as of October 7, 2011 electronic submission

BASIS OF APPROVAL:

• Was this approval based upon a petition? No
• What is the RLD on the 356(h) form: Derma-Smoothe/FS Topical Oil, 0.01% (Scalp Oil)
• NDA Number: 19-452
• NDA Drug Name: Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil)
• NDA Firm: Hill Laboratories, Inc.
• Date of Approval of NDA Insert and supplement: NDA 19-452/S016: Approved November 9, 2005
• Has this been verified by the MIS system for the NDA? Yes
• Was this approval based upon an OGD labeling guidance? No
• Basis of Approval for the Container Labels: Side-by-side comparison
• Basis of Approval for the Carton Labeling: Side-by-side comparison
• Revisions needed post-approval: NO
• Comments: The firm has revised their insert labeling, submitted May 13, 2011, to remove the labeling statements describing the testing methodology for peanut proteins as per guidance from the agency. Please note that the Description section of the package insert mentions that the formulation is also marketed as Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) as does the RLD. Therefore ANDA 201764 (body oil) and ANDA 201759 (Scalp Oil) needs to be approved at the same time.
• Patents/Exclusivities: Refer to chart below.

Patent Data – NDA 19-452

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>There are no unexpired patents for this product in the Orange Book Database.</td>
<td>II</td>
<td>none</td>
</tr>
</tbody>
</table>

Exclusivity Data– NDA 19-452

<table>
<thead>
<tr>
<th>Code</th>
<th>Reference</th>
<th>Expiration</th>
<th>Labeling Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>NONE</td>
<td>There is no unexpired exclusivity for this product in the Orange Book Database.</td>
<td>N/A</td>
<td>NONE</td>
</tr>
</tbody>
</table>

Reference ID: 3027678
QUESTIONS to Chemist: Emailed question to Jim Fan: The firm states that the statement which is in the RLD labeling “Importantly, the bulk peanut oil NF, used in fluocinolone acetonide oil is heated at 475° F for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins” does pertain to their Fluocinolone Acetonide Oil products.

The firm states that their bulk peanut oil is also heated at 475° F for at least 15 minutes. Can you please confirm that the above statement is correct. (Answer on next page)

ANSWER: Hi, Beverly

We have asked the firm about the manufacturing process for the refined peanut oil in our Review#1 (see deficiency below):
Please provide a process description, including the processing temperature for the refined peanut oil, NF. Also, please provide a commitment statement to pledge that a supplemental application is required to change peanut oil suppliers.

In Review#2, the firm provide their response, which clearly describes the heating at 475° F for at least 15 minutes.

The firm’s response: While conducting our search for raw material suppliers, we discovered a patent held by Hill Dermaceuticals for fluorouracil in topical cream containing peanut oil. A copy of the patent is provided in Module 3.3 Literature On page 2, item number 10, this patent lists Peanut Oil from Welch, Holme and Clark as one of interest that is suitable for use. Since Hill is the manufacturer of the RLD, we concluded that they are most likely using this Peanut Oil, NF is heated at 475° F for at least 15 minutes. Identi commits to file a supplemental application in the event that we need to change the Peanut Oil, NF vendor.

Reviewer’s assessment: The firm provided a commitment statement to pledge that a supplemental application is required to change peanut oil suppliers. The firm also included the processing temperature for refine peanut oil (475° F=246.1° C ), which is in the temperature range specified in USP (230° C to 260° C ). Based on the firm’s investigation, it is quite possible, but not certain that Hill, the manufacturer of the RLD uses peanut oil from Welch, Holme and Clark. The firm’s response is acceptable.

Therefore, the refined peanut oil used by Identi Pharma is indeed heated at 475° F for at least 15 minutes, according to their amendment.

Richard Chang

FOR THE RECORD:

1. MODEL LABELING
   Labeling review based on the labeling of the reference listed drug, Derma-Smoothe/FS Topical Oil, 0.01% (Scalp Oil) manufactured by Hill Laboratories, Inc., (NDA19-452/S-016: Approved November 9, 2005).

LABELING ISSUES – Memo filed in Darths: This Memo was regarding the basis for the ANDA labeling carve-out of information relating to peanut protein in the labeling for fluocinolone products that reference Hill Dermaceutical’s Dema-Smoothe (NDA 19-452). The office of Generic Drugs recommended the statements regarding the amount of residual peanut protein and test method be removed from the insert labeling.

FDA has determined that there is no validated assay for residual peanut protein. FDA has further determined that any peanut oil that is fully refined in accordance with the USP NF process is sufficiently safe for use in topical fluocinolone products and cannot be reliably determined to be safer for peanut allergic individuals than any other peanut oil refined in accordance with the USP NF process. As a result, when manufacturers use peanut oil that is fully refined in accordance with the USP NF process, FDA has
determined that the addition of a test to quantitate protein in refined peanut oil would not improve the safety of products formulated with this excipient and will not be required. (CP response at 30.) Accordingly, FDA has determined that no product, NDA or ANDA, should reference in its labeling an unvalidated assay for peanut protein (such as the S-ELISA test or the amino acid test) that implies an additional safety benefit that has not been shown to exist.

In this case, the Hill fluocinolone labeling includes information about assays for peanut protein that have not been validated and FDA has asked Hill to remove references to these assays from the Derma-Smoothe labeling. Although Hill has not yet complied with FDA’s request, FDA stands by its conclusion that, based on the information before it, the references to unvalidated assays in the Derma-Smoothe labeling are misleading and should be removed. Given FDA’s conclusions about peanut oil in general and the unvalidated nature of the S-ELISA and amino acid assays as described in the Hill CP response and FDA believes that ANDA applicants referencing Derma-Smoothe should not be required to include this unnecessary and misleading information in their labeling.

Accordingly, FDA concludes that ANDA applicants can remove references to assays for residual peanut protein from their labeling to comply with the labeling guidelines that FDA has provided to Hill. The resulting difference between ANDA and RLD labeling is a permitted difference due to difference in manufacturer within the meaning of the statute and regulations.

**Labeling outcome:** It has been recommended that the generic firms do not include in their labeling the statements describing the testing methodology for peanut proteins.

**Remove:**

Body Oil: The peanut oil used in Derma-Smooth/FS is tested for peanut proteins through amino acid analysis which can detect the quantity of amino acids to below 0.5 parts per million

and

Scalp Oil or Ear Drops: “Peanut oil used in this product is routinely tested for peanut proteins using a sandwich enzyme-linked immunosorbent assay test (S-ELISA) kit, which can detect peanut proteins to as low as 2.5 parts per million (ppm)”

2. PATENTS/EXCLUSIVITIES

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>There are no unexpired patents for this product in the Orange Book Database.</td>
<td>II</td>
<td>none</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Code</th>
<th>Reference</th>
<th>Expiration</th>
<th>Labeling Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>NONE</td>
<td>There is no unexpired exclusivity for this product in the Orange Book Database.</td>
<td>N/A</td>
<td>NONE</td>
</tr>
</tbody>
</table>

3. PACKAGING CONFIGURATION

- **RLD:** 4 oz bottle with 2 shower caps
- **ANDA:** 4 oz bottle with two shower caps

4. CONTAINER/CLOSURE - Fluocinolone Acetonide Oil, 0.01% is a clear, colorless to light straw colored liquid. Fluocinolone acetonide oil will be marketed in the following package: 4 oz round bottle with a (b) (d) screw cap and a wrap around label. The product is placed in the carton with a white (b) (d) dispensing cap.
5. **INACTIVE INGREDIENTS** - There does not appear to be a discrepancy in inactives between the DESCRIPTION and the composition statement. The proposed formulation falls within the FDA guidelines for all components and contains the same components as the RLD.

6. **STORAGE TEMPERATURE RECOMMENDATION COMPARISON**

   RLD – Store at 25°C (68°-77°F); excursions permitted to 15-30°C (59-86°F). [see USP Controlled Room Temperature] Keep tightly closed.

   ANDA – Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [see USP Controlled Room Temperature] Keep tightly closed.

7. **FINISHED DOSAGE FORM**

   - RLD – Scalp Oil
   - ANDA - A colorless to straw colored liquid (Labeled as Scalp Oil).

8. **MANUFACTURING FACILITY OF FINISHED DOSAGE FORM**

   Amneal Pharmaceuticals
   Branchburgh, NJ 08876

---

**Summary of Container Closure System with Configuration and Composition**

<table>
<thead>
<tr>
<th>Package</th>
<th>Configuration</th>
</tr>
</thead>
<tbody>
<tr>
<td>119.28 mL fill</td>
<td>• 4 ounce white round bottle with continuous thread white closure with dispenser closure (white cap)</td>
</tr>
<tr>
<td></td>
<td>• Container label</td>
</tr>
<tr>
<td></td>
<td>• Insert</td>
</tr>
<tr>
<td></td>
<td>• Carton</td>
</tr>
</tbody>
</table>

---

Date of Submission: October 4, 2011
Primary Reviewer: Beverly Weitzman
Team Leader: John Grace

Reference ID: 3027678
FLUCINOLONE ACETONIDE 0.01% Topical Oil

SCALP OIL

Contains: Fluocinolone acetonide (0.01%), isoamyl alcohol (7.2%), in a base containing isopropyl myristate, light mineral oil, cetyl-2 and refined peanut oil NF.

Contents of Package: 4 fl oz, bottle/2 shower caps.

Storage: Keep tightly closed. Store upright at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].

Rx only

Manufactured by: Amneal Pharmaceuticals, Branchburg, NJ 08876

Distributed by: Amneal Pharmaceuticals, Grandin, NY 14144

NDC 65162-703-86

Fluocinolone Acetonide 0.01% Topical Oil

FOR TOPICAL USE ONLY
NOT FOR ORAL, OPHTHALMIC or INTRAVAGINAL USE
SHAKE WELL BEFORE USE

Keep Out of Reach of Children

DOSAGE AND ADMINISTRATION: For the treatment of scalp psoriasis, wet or dampen hair and scalp thoroughly. Apply a thin film of Fluocinolone Acetonide 0.01% Topical Oil on the scalp, massage well and cover scalp with one of the supplied shower caps. Leave on overnight or for a minimum of 4 hours before washing off. Wash hair with regular shampoo and rinse thoroughly.

Rx only

Net Contents 118.28 mL (4 fl oz.)

LOT

Rev. 10-2010

Label size: 4” x 4”
Fluocinolone Acetonide 0.01% Topical Oil

SCALP OIL

Contains: Fluocinolone acetonide (0.01%), isopropyl alcohol (0.9%), and a base containing caprylyl methylcyclopentadecyl ether, light mineral oil, dioctyl adipate, and refined peanut oil.

Contents of Package: 4 fl oz, bottles of 2 shower caps.

Storage: Keep tightly closed, Store upright at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) (see USP Controlled Room Temperature).

Keep Out of Reach of Children

FOR TOPICAL USE ONLY NOT FOR ORAL, OPHTHALMIC or INTRAVAGINAL USE SHAKE WELL BEFORE USE

Rx only

Net Contents 118.28 ml (4 fl oz)
Rev. 10-2010

Manufactured by: Amneal Pharmaceuticals Inc., Bridgewater, NJ 08807

Revised by: Amneal Pharmaceuticals Inc., Bridgewater, NJ 08807

Dosage and Administration:
For the treatment of scalp psoriasis, wet or dampen hair and scalp thoroughly. Apply a thin film of Fluocinolone Acetonide 0.01% Topical Oil on the scalp, massage well and cover scalp with one of the supplied shower caps. Leave on overnight or for a minimum of 4 hours before washing off. Wash hair with regular shampoo and rinse thoroughly.

See package insert for full prescribing information.

Rx only

Net Contents 118.28 ml (4 fl oz)
Rev. 10-2010

Lot: EXP:
Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)

For Topical Use Only. Not for Oral, Ophthalmic, or Intravaginal Use

DESCRIPTION
Fluocinolone Acetonide 0.01% Topical Oil contains fluocinolone acetonide (6α, 11β, 16α)-6,9-difluoro-11,12-dihydyroxy-16[(1-methylethylidene)oxy]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone), a synthetic corticosteroid for topical use. This compound is also marketed as Fluocinolone Acetonide 0.01% Topical Oil for use as body oil for atopic dermatitis in adults and for moderate to severe atopic dermatitis in infants and children ages 7 to 12 years (see CLINICAL STUDIES). It is a white crystalline powder that is odorless, stable in light, and melts 7°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.

Each gram of Fluocinolone Acetonide 0.01% Topical Oil contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl palmitate, light mineral oil, and refined peanut oil NF.

Each packaged product contains 2 shower caps. The shower cap is made of low density polyethylene material with rubber elastic.

CLINICAL PHARMACOLOGY
Like all topical corticosteroids, fluocinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by inhibiting phospholipase A2, inhibiting cytokines, cellmediated and humoral immunity, and release of their precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusion of topical corticosteroids can enhance penetration. Topical corticosteroids can be absorbed from normal intact skin. Also, inflammation and/or other disease processes in the skin can increase percutaneous absorption.

Fluocinolone Acetonide 0.01% Topical Oil is in the low to medium range of potency as compared with other topical corticosteroids.

CLINICAL STUDIES
In a vehicle-controlled study for the treatment of psoriasis of the scalp in adults, after 21 days of treatment, 60% of patients on active treatment and 21% of patients on the placebo had excellent to cleared clinical response.

Open-label safety studies on 33 children (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe atopic dermatitis, and baseline body surface area involvement greater than 75% in 18 patients, and 50% to 75% in 15 patients were treated with fluocinolone acetonide 0.01% twice daily for 4 weeks. Moring pre-stimulation cortisol level and post-Cortrosyn stimulation cortisol level were obtained at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pretreatment cortisol levels (3.2 to 6.6 µg/dL; normal: cortisol > 7 µg/dL) but all had normal post-Cortrosyn levels. (25 mg of Cortrosyn was administered to each subject.) A clinical study was conducted to assess the safety of fluocinolone acetonide 0.01%, which contains refined peanut oil, on subjects with known peanut allergies. The study enrolled 13 patients with food dermatitis, 6 to 17 years of age. Of the 13 patients, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The study evaluated the responses to both prick test and patch testing refined peanut oil NF. Fluocinolone acetonide topical 0.01% and histamine/saline controls, on the 13 individuals. These subjects were also treated with fluocinolone acetonide 0.01% topical oil twice daily for 7 days. Prick test and patch test results showed all 13 patients were negative to fluocinolone acetonide 0.01% oil and refined peanut oil. One of the 9 peanut-sensitive patients experienced an exacerbation of atopic dermatitis after 5 days of fluocinolone acetonide 0.01% topical oil use. Importantly, the bulk peanut oil NF, used in fluocinolone acetonide 0.01% topical oil is heated at 475°F for at least 15 minutes, which should provide for adequate decomposition of allergic proteins.

INDICATION AND USAGE
Fluocinolone Acetonide 0.01% Topical Oil is a low to medium potency corticosteroid indicated for:

- Atopic dermatitis, secondary infection, skin atrophy, striae, and malaria. One peanut sensitive adult with a history of severe atopic dermatitis was treated with fluocinolone acetonide 0.01% topical oil (see CLINICAL STUDIES).
- Diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper or plastic pants may constitute occlusive dressing.

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil in the treatment of diaper dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area, as diaper or plastic pants may constitute occlusive dressing.
5. This medication should not be used on the face, underarm, or groin directed by the physician.
6. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician.

Laboratory Tests: The following tests may be helpful in evaluating patients for HPA axis suppression:
- ACHT stimulation test
- A.M. plasma cortisol test
- Urine free cortisol test

Carcinogenesis, mutagenesis, and impairment of fertility:
Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of Fluocinolone Acetonide 0.01% Topical Oil. Studies have not been performed to evaluate the mutagenic potential of fluocinolone acetonide, the active ingredient in Fluocinolone Acetonide 0.01% Topical Oil. Some corticosteroids have been found to be genotoxic in various genotoxicity tests (i.e. in the in vitro human peripheral blood lymphocyte chromosome aberration assay and in the in vivo mouse bone marrow micronucleus assay). The clinical relevance of the in vitro mouse lymphoma gene mutation assay is not currently known.

Pregnancy: Teratogenic effects: Pregnancy category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from Fluocinolone Acetonide 0.01% Topical Oil. Therefore, Fluocinolone Acetonide 0.01% Topical Oil should not be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fluocinolone Acetonide 0.01% Topical Oil is administered to a nursing woman.

Pediatric Use: Fluocinolone Acetonide 0.01% Topical Oil may be used twice daily for up to 4 weeks in pediatric patients 2 years and older to moderate to severe atopic dermatitis. Fluocinolone Acetonide 0.01% Topical Oil should not be applied to the diaper area.

Application to intertriginous areas should be avoided due to the increased possibility of local adverse events such as striae, atrophy, and telangiectasia, which may be irreversible. The smallest amount of drug needed to cover the affected areas should be applied. Long-term safety in the pediatric population has not been established.

Fluocinolone Acetonide 0.01% Topical Oil is not recommended for use on the face (See ADVERSE REACTIONS section).

Because of a higher ratio of skin surface area to body mass, children are at a greater risk than adults of HPA-axis-suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushings syndrome while on treatment. Adverse effects including stress have been reported with inappropriate use of topical corticosteroids in children and infants. (See PRECAUTIONS). HPA axis suppression, Cushings syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bitemporal flattening.

Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals.

ADVERSE REACTIONS
The following local adverse reactions have been reported infrequently with topical corticosteroids. They may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. In addition, infections may occur occurring supplemental systemic corticosteroids. For information on systemic suppression, see prescribing information for those products.

Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS: Pediatric use)
for 4 weeks to the face in children (2 to 12 years) with moderate to severe atopic dermatitis (see Table of Incidence of Adverse Events).

### Incidence of Adverse Events (%)

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th># of patients (%)</th>
<th>Day 14</th>
<th>Day 28**</th>
<th>Day 56***</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telangectasia</td>
<td>5 (8.6)</td>
<td>3 (5.2)</td>
<td>4 (6.9)</td>
<td>2 (3.5)</td>
</tr>
<tr>
<td>Erythema</td>
<td>3 (5.2)</td>
<td>3 (5.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itching</td>
<td>3 (5.2)</td>
<td>3 (5.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irritation</td>
<td>3 (5.2)</td>
<td>3 (5.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Numbness</td>
<td>3 (5.2)</td>
<td>3 (5.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypopigmentation</td>
<td>2 (3.5)</td>
<td>2 (3.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry skin</td>
<td>4 (6.9)</td>
<td>1 (1.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary atopic dermatitis</td>
<td>1 (1.7)</td>
<td></td>
<td>1 (1.7)</td>
<td></td>
</tr>
<tr>
<td>Papules and pustules</td>
<td>1 (1.7)</td>
<td></td>
<td>1 (1.7)</td>
<td></td>
</tr>
<tr>
<td>Keratosis pilaris</td>
<td>1 (1.7)</td>
<td></td>
<td>1 (1.7)</td>
<td></td>
</tr>
<tr>
<td>Folliculitis</td>
<td>1 (1.7)</td>
<td>1 (1.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial herpes simplex</td>
<td>1 (1.7)</td>
<td>1 (1.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acneiform eruption</td>
<td>1 (1.7)</td>
<td>1 (1.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear infection</td>
<td>1 (1.7)</td>
<td>1 (1.7)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The number of individual adverse events reported does not necessarily reflect the number of individual subjects, since one subject could have multiple reporting of an adverse event.

**End of Treatment

### OVERDOSAGE

Topically applied Fluocinolone Acetonide 0.01% Topical Oil can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

### DOSAGE AND ADMINISTRATION

Fluocinolone Acetonide 0.01% Topical Oil for scalp psoriasis in adults (Scalp Oil):

For the treatment of scalp psoriasis, wet or dampen hair and scalp thoroughly. Apply a thin film of Fluocinolone Acetonide 0.01% Topical Oil on the scalp, massage well and cover scalp with the supplied shower cap. Leave on overnight, or for a minimum of 4 hours before washing off. Wash hair with regular shampoo and rinse thoroughly.

### HOW SUPPLIED

Fluocinolone Acetonide 0.01% Topical Oil is supplied in a 4 fluid ounce bottle with a net content of 118.28 mL. It is labeled as Scalp Oil (NDC 65162-703-86). Scalp Oil is supplied with 2 shower caps.

Keep tightly closed. Store upright at 25° C (68 to 77° F); excursions permitted to 15°-30° C (59°-86°F) (see USP Controlled Room Temperature).

MAXIMUM DOSE: Rx only

### MANUFACTURED BY:

Amneal Pharmaceuticals
Branchburg, NJ 08876

### DISTRIBUTED BY:

Amneal Pharmaceuticals
Glasgow, KY 42141

Rev. 05-2011
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BEVERLY WEITZMAN
10/12/2011

JOHN F GRACE
10/12/2011
ANDA Number: 201759
Date of Submission: November 9, 2010 and May 12, 2011
Applicant's Name: Identi Pharmaceuticals, LLC.
Established Name: Fluocinolone Acetonide Oil, 0.01% (Scalp Oil)

Labeling Comments:

1. **CONTAINER:** Satisfactory in DRAFT.
2. **CARTON:** Satisfactory in DRAFT.
3. **INSERT:** Satisfactory in Final Print.

Submit final printed labeling electronically.
Prior to approval, it may be necessary to revise your labeling subsequent to approved changes for the reference listed drug. In order to keep ANDA labeling current, we suggest that you subscribe to the daily or weekly updates of new documents posted on the CDER web site at the following address -

REMS required? NO
MedGuides and/or PPIs (505-1(e)) □ Yes □ No
Communication plan (505-1(e)) □ Yes □ No
Elements to assure safe use (ETASU) (505-1(f)(3)) □ Yes □ No
Implementation system if certain ETASU (505-1(f)(4)) □ Yes □ No
Timetable for assessment (505-1(d)) □ Yes □ No

ANDA REMS acceptable? □ Yes □ No □ n/a

APPROVAL SUMMARY (List the package size, strength(s), and date of submission for approval):
Do you have Final Printed Labels and Labeling?

1. CONTAINER (4 oz bottle) - Satisfactory in DRAFT as of November 9, 2010 electronic submission.
2. CARTON (4 oz bottle) – Satisfactory in DRAFT as of November 9, 2010 electronic submission.
3. PACKAGE INSERT – Satisfactory in Final Print as of May 12, 2011 electronic submission

BASIS OF APPROVAL:
• Was this approval based upon a petition? No
• What is the RLD on the 356(h) form: Derma-Smoothe/FS Topical Oil, 0.01% (Scalp Oil)
• NDA Number: 19-452
• NDA Drug Name: Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil)
• NDA Firm: Hill Laboratories, Inc.
• Date of Approval of NDA Insert and supplement: NDA 19-452/S016: Approved November 9, 2005
• Has this been verified by the MIS system for the NDA? Yes
• Was this approval based upon an OGD labeling guidance? No
• Basis of Approval for the Container Labels: Side-by-side comparison
• Basis of Approval for the Carton Labeling: Side-by-side comparison
• Revisions needed post-approval: NO
• Comments: The firm has revised their insert labeling, submitted May 13, 2011, to remove the labeling statements describing the testing methodology for peanut proteins as per guidance from the agency. Please note that the Description section of the package insert mentions that the formulation is also marketed as Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) as does the RLD. Therefore ANDA 201764 (body oil) and ANDA 201759 (Scalp Oil) needs to be approved at the same time.
• Patents/Exclusivities: Refer to chart below.

Patent Data – NDA 19-452

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>There are no unexpired patents for this product in the Orange Book Database.</td>
<td>II</td>
<td>none</td>
</tr>
</tbody>
</table>

Exclusivity Data– NDA 19-452

<table>
<thead>
<tr>
<th>Code</th>
<th>Reference</th>
<th>Expiration</th>
<th>Labeling Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>NONE</td>
<td>There is no unexpired exclusivity for this product in the Orange Book Database.</td>
<td>N/A</td>
<td>NONE</td>
</tr>
</tbody>
</table>

QUESTIONS to Chemist: Emailed question to Jim Fan: The firm states that the statement which is in the RLD labeling “Importantly, the bulk peanut oil NF, used in fluocinolone acetonide oil is heated at 475° F for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins” does pertain to their Fluocinolone Acetonide Oil products.

The firm states that their bulk peanut oil is also heated at 475° F for at least 15 minutes.
Can you please confirm that the above statement is correct. (Answer on next page)
ANSWER: Hi, Beverly

We have asked the firm about the manufacturing process for the refined peanut oil in our Review#1 (see deficiency below):
Please provide a process description, including the processing temperature for the refined peanut oil, NF. Also, please provide a commitment statement to pledge that a supplemental application is required to change peanut oil suppliers.

In Review#2, the firm provide their response, which clearly describes the heating at 475° F for at least 15 minutes.

The firm’s response: While conducting our search for raw material suppliers, we discovered a patent held by Hill Dermaceuticals for fluorouracil in topical cream containing peanut oil. A copy of the patent is provided in Module 3.3 Literature On page 2, item number 10, this patent lists Peanut Oil from Welch, Holme and Clark as one of interest that is suitable for use. Since Hill is the manufacturer of the RLD, we concluded that they are most likely using this Peanut Oil, NF is heated at 475° F for at least 15 minutes. Identi commits to file a supplemental application in the event that we need to change the Peanut Oil, NF vendor.

Reviewer’s assessment: The firm provided a commitment statement to pledge that a supplemental application is required to change peanut oil suppliers. The firm also included the processing temperature for refine peanut oil (475° F=246.1° C), which is in the temperature range specified in USP (230° C to 260° C). Based on the firm’s investigation, it is quite possible, but not certain that Hill, the manufacturer of the RLD uses peanut oil from Welch, Holme and Clark. The firm’s response is acceptable.

Therefore, the refined peanut oil used by Identi Pharma is indeed heated at 475° F for at least 15 minutes, according to their amendment.

Richard Chang

FOR THE RECORD:

1. MODEL LABELING
Labeling review based on the labeling of the reference listed drug, Derma-Smoother/FS Topical Oil, 0.01% (Scalp Oil) manufactured by Hill Laboratories, Inc., (NDA19-452/S-016: Approved November 9, 2005).

LABELING ISSUES – Memo filed in Darats: This Memo was regarding the basis for the ANDA labeling carve-out of information relating to peanut protein in the labeling for fluocinolone products that reference Hill Dermaceutical’s Dema-Smoother (NDA 19-452). The office of Generic Drugs recommended the statements regarding the amount of residual peanut protein and test method be removed from the insert labeling.

FDA has determined that there is no validated assay for residual peanut protein. FDA has further determined that any peanut oil that is fully refined in accordance with the USP NF process is sufficiently safe for use in topical fluocinolone products and cannot be reliably determined to be safer for peanut allergic individuals than any other peanut oil refined in accordance with the USP NF process. As a result, when manufacturers use peanut oil that is fully refined in accordance with the USP NF process, FDA has determined that the addition of a test to quantitate protein in refined peanut oil would not improve the safety of products formulated with this excipient and will not be required. (CP response at 30.) Accordingly, FDA has determined that no product, NDA or ANDA, should reference in its labeling an unvalidated assay for peanut protein (such as the S-ELISA test or the amino acid test) that implies an additional safety benefit that has not been shown to exist.

In this case, the Hill fluocinolone labeling includes information about assays for peanut protein that have not been validated and FDA has asked Hill to remove references to these assays from the Derma-Smoother labeling. Although Hill has not yet complied with FDA’s request, FDA stands by its conclusion that, based on the information before it, the references to unvalidated assays in the Derma-Smoother labeling are misleading and should be removed. Given FDA’s conclusions about peanut oil in general and the unvalidated nature of the S-ELISA and amino acid assays as described in the Hill CP response and FDA believes that ANDA applicants referencing Derma-Smoother
should not be required to include this unnecessary and misleading information in their labeling.

Accordingly, FDA concludes that ANDA applicants can remove references to assays for residual peanut protein from their labeling to comply with the labeling guidelines that FDA has provided to Hill. The resulting difference between ANDA and RLD labeling is a permitted difference due to difference in manufacturer within the meaning of the statute and regulations.

Labeling outcome: It has been recommended that the generic firms do not include in their labeling the statements describing the testing methodology for peanut proteins.

Remove:
Body Oil: The peanut oil used in Derma-Smooth/FS is tested for peanut proteins through amino acid analysis which can detect the quantity of amino acids to below 0.5 parts per million and

Scalp Oil or Ear Drops: “Peanut oil used in this product is routinely tested for peanut proteins using a sandwich enzyme-linked immunosorbent assay test(S-ELISA) kit, which can detect peanut proteins to as low as 2.5 parts per million (ppm)”

2. PATENTS/EXCLUSIVITIES

<table>
<thead>
<tr>
<th>Patent Data – NDA 19-452</th>
</tr>
</thead>
<tbody>
<tr>
<td>------------</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusivity Data– NDA 19-452</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code</td>
</tr>
<tr>
<td>NONE</td>
</tr>
</tbody>
</table>

3. PACKAGING CONFIGURATION
- **RLD**: 4 oz bottle with 2 shower caps
- **ANDA**: 4 oz bottle with two shower caps

4. CONTAINER/CLOSURE - Fluocinolone Acetonide Oil, 0.01% is a clear, colorless to light straw colored liquid. Fluocinolone acetonide oil will be marketed in the following package; 4 oz round bottle with a screw cap and a wrap around label. The product is placed in the carton with a white dispensing cap.

<table>
<thead>
<tr>
<th>Summary of Container Closure System with Configuration and Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Package</td>
</tr>
<tr>
<td>119.28 mL fill</td>
</tr>
</tbody>
</table>

5. INACTIVE INGREDIENTS - There does not appear to be a discrepancy in inactives between the DESCRIPTION and the composition statement. The proposed formulation falls within the FDA guidelines for all components and contains the same components as the RLD.

6. STORAGE TEMPERATURE RECOMMENDATION COMPARISON
- **RLD** – Store at 25°C (68°-77°F); excursions permitted to 15-30°C (59-86°F). [see USP Controlled Room Temperature] Keep tightly closed.
- **ANDA** – Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [see USP Controlled Room Temperature] Keep tightly closed.
Room Temperature] Keep tightly closed.

7. FINISHED DOSAGE FORM
   • RLD – Scalp Oil
   • ANDA - A colorless to straw colored liquid (Labeled as Scalp Oil).

8. MANUFACTURING FACILITY OF FINISHED DOSAGE FORM
   Amneal Pharmaceuticals
   Branchburgh, NJ 08876

Date of Submission: November 9, 2010 and May 12, 2011

Primary Reviewer: Beverly Weitzman Date:
Team Leader: John Grace Date:
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BEVERLY WEITZMAN
10/07/2011

JOHN F GRACE
10/12/2011
ANCA 201759

Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)

Identi Pharmaceuticals Inc.

Richard Chang
Chemistry I
Table of Contents

Table of Contents............................................................................................................. 2

Chemistry Review Data Sheet ...................................................................................... 3

The Executive Summary.............................................................................................. 8

I. Recommendations........................................................................................................... 8
   A. Recommendation and Conclusion on Approvability .............................................. 8
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable ......................................................... 8

II. Summary of Chemistry Assessments ....................................................................... 8
   A. Description of the Drug Product(s) and Drug Substance(s) ................................ 8
   B. Description of How the Drug Product is Intended to be Used ............................. 8
   C. Basis for Approvability or Not-approval Recommendation .................................. 9

Chemistry Assessment ............................................................................................... 10
Chemistry Review Data Sheet

1. ANDA 201759

2. REVIEW #: 4

3. REVIEW DATE: October 03, 2011

4. REVIEWER: Richard Chang

5. PREVIOUS DOCUMENTS:
   - Original submission: November 09, 2010
   - Amendment: December 29, 2010
   - Amendment: January 10, 2011
   - Gratuitous Amendment: January 13, 2011
   - Acceptable for filing: November 10, 2010
   - Amendment: May 12, 2011
   - Amendment: August 22, 2011

6. SUBMISSION(S) BEING REVIEWED:
   - Submission(s) Reviewed
   - Document Date
     Amendment September 29, 2011

7. NAME & ADDRESS OF APPLICANT:
   - Name: Identi Pharmaceuticals Inc.
   - Address: 2224 W. Northern Ave.
     Suite# D-300
     Phoenix, Arisona 85021

     6333 Summercrest Drive
     Columbia, MD 21045
     Contact person: Jeanne Taborsky

8. DRUG PRODUCT NAME/CODE/TYPEx:
   - a) Proprietary Name: N/A
   - Non-Proprietary Name (USAN): Fluocinolone Acetonide Oil 0.01 % Topical Oil (Scalp Oil)

Reference ID: 3028590
9. LEGAL BASIS FOR SUBMISSION:

The Reference Listed Drug is Hill’s Derma-Smoothe/FS® fluocinolone acetonide 0.01% Topical Oil (Scalp Oil) (NDA 019452)

PATENT CERTIFICATION STATEMENT

Identi Pharmaceuticals provided a statement of patent certification for the Abbreviated New Drug Application for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil).

Also presented is a marketing exclusivity statement required under 21 CFR Section 314.94(a)(3)(ii).

PATENT INFORMATION

Identi Pharmaceuticals’ proposed drug product is the generic version of Hill Dermaceuticals’ Derma-Smoothe®, pursuant to NDA 019452. There are no unexpired patents for this drug product in the FDA listing titled Electronic Orange Book- Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as Orange Book). Identi Pharmaceuticals provided a Paragraph II certification for their drug product, Fluocinolone Acetonide Oil, 0.01%.

EXCLUSIVITY STATEMENT

The firm also provided an exclusivity statement to state that there is no unexpired exclusivity for this drug product.

10. PHARMACOL. CATEGORY:

Glucocorticoid and indicated for the treatment of scalp psoriasis and atopic dermatitis in adults and for moderate to severe atopic dermatitis pediatric patients 2 years old and older.

11. DOSAGE FORM: Topical Oil (Scalp Oil)

12. STRENGTH/POTENCY: 0.01%

13. ROUTE OF ADMINISTRATION: Topical

14. Rx/OTC DISPENSED: __x_Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):

_____SPOTS product – Form Completed

_____x__ Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

**Compendial name:** fluocinolone acetonide, USP

**Chemical name:** Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-6α,9-Difluoro-11β,16α,17,21-tetrahydroxyprogna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone

**Molecular formula:** C_{24}H_{30}F_{2}O_{6} (anhydrous)

**Molecular weight:** 452.50

**Structure:**

![](image)

17. RELATED/SUPPORTING DOCUMENTS:

**A. DMFs:**

<table>
<thead>
<tr>
<th>DMF #</th>
<th>Type</th>
<th>Item referenced</th>
<th>Holder</th>
<th>Code¹/Status²</th>
<th>Date review completed</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1/Adequate</td>
<td>04/01/11</td>
<td>Reviewed by Richard Chang</td>
</tr>
</tbody>
</table>

| 4     |      |                 |        |               |                       |          |
| 4     |      |                 |        |               |                       |          |
| 4     |      |                 |        |               |                       |          |
| 4     |      |                 |        |               |                       |          |
| 4     |      |                 |        |               |                       |          |
Action codes for DMF Table: 1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF; 3 – Reviewed previously and no revision since last review; 4 – Sufficient information in application; 5 – Authority to reference not granted; 6 – DMF not available; 7 – Other (explain under "Comments"); 8 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents: N/A

18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>8/10/11</td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>Acceptable</td>
<td>10/12/11</td>
<td>B. Weitzman</td>
</tr>
<tr>
<td>Bioequivalence</td>
<td>Bio-waiver granted</td>
<td>9/16/11</td>
<td>N. Lee</td>
</tr>
<tr>
<td>EA</td>
<td>Satisfactory (exclusion requested)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW

The application submission(s) covered by this review was taken in the date order of receipt.

_X___ Yes   ____ No       If no, explain reason(s) below:
The Chemistry Review for ANDA 201759

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on approvability

This ANDA is approvable.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if approvable

N/A

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Drug product

Fluocinolone Acetonide 0.01% Topical Oil contains fluocinolone acetonide which is a synthetic, fluorinated corticosteroid. It is intended for topical dermatologic use for the relief of the inflammatory and pruritic manifestation of atopic dermatitis in patients 1 year or older. Each gram of Fluocinolone Acetonide Oil, 0.01% contains 0.11 mg fluocinolone acetonide per mL in an oil consisting of isopropyl alcohol USP, refined peanut oil NF, isopropyl myristate NF, Oleth-2 and light mineral oil NF.

Fluocinolone Acetonide Oil, 0.01% is a clear, colorless to light straw colored liquid. Fluocinolone acetonide oil will be marketed in the following package; 120 mL (4 oz) round bottle with a screw cap and a wrap around label. The product is placed in the carton with a white dispensing cap, medication guide and insert.

It is to be stored in controlled room temperature and shipped at cool or refrigerated conditions. The proposed expiration dating for the drug product is 24 months.

Drug substance

The chemical name of fluocinolone acetonide is Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[1-methylethylidene]bis(oxy)]-(6a,11β,16a)-6a,9-Difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone. The drug substance is listed in the USP Monograph. It is a white to practically white crystalline powder. It is insoluble in water, freely soluble in acetone and glacial acetic acid, sparingly soluble in chloroform and methanol, and very slightly soluble in ether.

B. Description of How the Drug Product is Intended to be Used

Fluocinolone Acetonide Oil, 0.01%, should be applied to the affected area as a thin film three times daily for adult patients with atopic dermatitis and twice daily for up to four weeks for pediatric patients with atopic dermatitis.

Maximum daily dose (MDD) (the firm’s calculation option 1)
The MDD is calculated below based on the package insert information from Derma-Smoother® Oil for Fluocinolone Acetonide Oil, 0.01% and 1 mL of oil can cover the affected area to form a thin film (See pages 27-28 of this review for more detailed discussion).

MDD = IT QT DS DP %

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DS</td>
<td>IT</td>
<td>QT</td>
</tr>
<tr>
<td>DP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C. Basis for approvability or Not-approval Recommendation

The ANDA is approvable.

Review Note for the amendment dated August 22, 2011

Identi is transferring the testing of the active pharmaceutical ingredient from [REDACTED] to Amneal Pharmaceuticals. Amneal will not be transferring the method for assay or impurities, but rather using the USP regulatory method to test assay, and the FDA reviewed API supplier method to test impurities. Amneal is already approved as the manufacturer, and as the testing lab for inactive ingredients and the finished product. The firm included a copy of the method verification report and the test method in the amendment. The assay method and related compounds method are verified and found to be specific and precise and rugged. The data for each validation characteristic described in the report meet the acceptance criteria indicating that the test methods are valid to determine assay and related compounds of Fluocinolone Acetonide. The ANDA (CMC) remains approvable.

Review Note for the amendment dated September 29, 2011

On September 26, 2011, the following deficiency was communicated with the firm and the firm responded on September 29, 2011:

Please remove the following tests and specifications from your drug product release and stability specifications:

The firm’s response: As requested, Identi removed the following tests and specifications from our drug product release and stability specifications:

Please submit a revised drug product release and stability specifications.

The revised method 701-AS-RC is provided herein.

Reviewer’s assessment: As requested, the firm revised the drug product release and stability specifications. The ANDA (CMC) remains approvable.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RICHARD CHANG
10/13/2011

TRANG Q TRAN
10/13/2011

JAMES M FAN
10/13/2011
ANDA 201759

Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)

Identti Pharmaceuticals Inc.

Richard Chang
Chemistry I
# Table of Contents

Table of Contents.................................................................................................................. 2

Chemistry Review Data Sheet............................................................................................. 3

The Executive Summary......................................................................................................... 8

I. Recommendations................................................................................................................ 8
   A. Recommendation and Conclusion on Approvability ......................................................... 8
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable................................................................. 8

II. Summary of Chemistry Assessments ................................................................................. 8
   A. Description of the Drug Product(s) and Drug Substance(s).............................................. 8
   B. Description of How the Drug Product is Intended to be Used ........................................ 8
   C. Basis for Approvability or Not-approval Recommendation............................................... 9

Chemistry Assessment ......................................................................................................... 10
Chemistry Review Data Sheet

1. ANDA 201759

2. REVIEW #: 3

3. REVIEW DATE: September 08, 2011

4. REVIEWER: Richard Chang

5. PREVIOUS DOCUMENTS:
   - Original submission
   - Amendment
   - Amendment
   - Gratuitous Amendment
   - Acceptable for filing
   - Amendment

   November 09, 2010
   December 29, 2010
   January 10, 2011
   January 13, 2011
   November 10, 2010
   May 12, 2011

6. SUBMISSION(S) BEING REVIEWED:
   - Submission(s) Reviewed
   - Amendment
   
   Document Date
   
   August 22, 2011

7. NAME & ADDRESS OF APPLICANT:

   Name: Identi Pharmaceuticals Inc.
   Address: 2224 W. Northern Ave.
            Suite# D-300
            Phoenix, Arisona 85021

             6333 Summercrest Drive
             Columbia, MD 21045
             Contact person: Jeanne Taborsky

8. DRUG PRODUCT NAME/ CODE/ TYPE:

   a) Proprietary Name: N/A
   Non-Proprietary Name (USAN): Fluocinolone Acetonide Oil 0.01 % Topical Oil
   (Scalp Oil)
9. LEGAL BASIS FOR SUBMISSION:

The Reference Listed Drug is Hill’s Derma-Smoother/FS® fluocinolone acetonide 0.01% Topical Oil (Scalp Oil) (NDA 019452)

PATENT CERTIFICATION STATEMENT

Identi Pharmaceuticals provided a statement of patent certification for the Abbreviated New Drug Application for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil).

Also presented is a marketing exclusivity statement required under 21 CFR Section 314.94(a)(3)(ii).

PATENT INFORMATION

Identi Pharmaceuticals’ proposed drug product is the generic version of Hill Dermaceuticals’ Derma-Smoother®, pursuant to NDA 019452. There are no unexpired patents for this drug product in the FDA listing titled Electronic Orange Book- Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as Orange Book). Identi Pharmaceuticals provided a Paragraph II certification for their drug product, Fluocinolone Acetonide Oil, 0.01%.

EXCLUSIVITY STATEMENT

The firm also provided an exclusivity statement to state that there is no unexpired exclusivity for this drug product.

10. PHARMACOL. CATEGORY:

Glucocorticoid and indicated for the treatment of scalp psoriasis and atopic dermatitis in adults and for moderate to severe atopic dermatitis pediatric patients 2 years old and older.

11. DOSAGE FORM: Topical Oil (Scalp Oil)

12. STRENGTH/POTENCY: 0.01%

13. ROUTE OF ADMINISTRATION: Topical

14. Rx/OTC DISPENSED: ___Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):

_____SPOTS product – Form Completed

____x__Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

**Compendial name:** fluocinolone acetonide, USP

**Chemical name:** Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-(6α,11β,16α)-6α,9-Difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone

**Molecular formula:** C_{24}H_{30}F_{2}O_{6} (anhydrous)

**Molecular weight:** 452.50

**Structure:**

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>Type</th>
<th>Item referenced</th>
<th>Holder</th>
<th>Code¹/ Status²</th>
<th>Date review completed</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>04/01/11</td>
<td>Reviewed by Richard Chang</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Chemistry Review Data Sheet**

1 Action codes for DMF Table:  1 – DMF Reviewed.  
Other codes indicate why the DMF was not reviewed, as follows:  
2 – Type 1 DMF; 3 – Reviewed previously and no revision since last review; 4 – Sufficient information in application; 5 – Authority to reference not granted; 6 – DMF not available; 7 – Other (explain under "Comments"); 2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents: N/A

18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>8/10/11</td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioequivalence</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Satisfactory (exclusion requested)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW

The application submission(s) covered by this review was taken in the date order of receipt.

_X___ Yes   ____ No       If no, explain reason(s) below:
The Chemistry Review for ANDA 201759

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on approvability

This ANDA is approvable (CMC). Labeling & Bio are pending.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if approvable

N/A

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Drug product
Fluocinolone Acetonide 0.01% Topical Oil contains fluocinolone acetonide which is a synthetic, fluorinated corticosteroid. It is intended for topical dermatologic use for the relief of the inflammatory and pruritic manifestation of atopic dermatitis in patients 1 year or older. Each gram of Fluocinolone Acetonide Oil, 0.01% contains 0.11 mg fluocinolone acetonide per mL in an oil consisting of isopropyl alcohol USP, refined peanut oil NF, isopropyl myristate NF, Oleth-2 and light mineral oil NF.

Fluocinolone Acetonide Oil, 0.01% is a clear, colorless to light straw colored liquid. Fluocinolone acetonide oil will be marketed in the following package; 120 mL (4 oz) round bottle with a screw cap and a wrap around label. The product is placed in the carton with a white dispensing cap, medication guide and insert.

It is to be stored in controlled room temperature and shipped at cool or refrigerated conditions. The proposed expiration dating for the drug product is 24 months.

Drug substance
The chemical name of fluocinolone acetonide is Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[1-methylene]bis(oxy)]-(6α,11β,16α)-6α,9-Difluoro-11β,16α,17,21-tetrahydroxy pregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone. The drug substance is listed in the USP Monograph. It is a white to practically white crystalline powder. It is insoluble in water, freely soluble in acetone and glacial acetic acid, sparingly soluble in chloroform and methanol, and very slightly soluble in ether.

B. Description of How the Drug Product is Intended to be Used

Fluocinolone Acetonide Oil, 0.01%, should be applied to the affected area as a thin film three times daily for adult patients with atopic dermatitis and twice daily for up to four weeks for pediatric patients with atopic dermatitis.

Maximum daily dose (MDD) (the firm’s calculation option 1)
The MDD is calculated below based on the package insert information from Derma-Smoothe® Oil for Fluocinolone Acetonide Oil, 0.01% and 1 mL of oil can cover the affected area to form a thin film (See pages 27-28 of this review for more detailed discussion).

\[ \text{MDD} = \frac{\text{IT}}{\text{QT}} \]

\[ \begin{array}{c|c|c}
\text{DS} & \text{IT} & \text{QT} \\
\hline
\text{(b) (4)}
\end{array} \]

\[ \begin{array}{c|c|c}
\text{DP} & \text{(b) (4)} & \text{(b) (4)} \\
\hline
\end{array} \]

C. Basis for approvability or Not-approval Recommendation

The ANDA is approvable (CMC). Labeling & bioequivalence reviews are pending.

Review Note for the amendment dated August 22, 2011

Ident is transferring the testing of the active pharmaceutical ingredient from [REDACTED] to Amneal Pharmaceuticals. Amneal will not be transferring the method for assay or impurities, but rather using the USP regulatory method to test assay, and the FDA reviewed API supplier method to test impurities. Amneal is already approved as the manufacturer, and as the testing lab for inactive ingredients and the finished product. The firm included a copy of the method verification report and the test method in the amendment. The assay method and related compounds method are verified and found to be specific and precise and rugged. The data for each validation characteristic described in the report meet the acceptance criteria indicating that the test methods are valid to determine assay and related compounds of Fluocinolone Acetonide. The ANDA (CMC) remains approvable.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RICHARD CHANG
09/15/2011

TRANG Q TRAN
09/15/2011

JAMES M FAN
09/16/2011
ANDA 201759

Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)

Identi Pharmaceuticals Inc.

Richard Chang
Chemistry I
# Table of Contents

Table of Contents........................................................................................................... 2

Chemistry Review Data Sheet........................................................................................... 3

The Executive Summary................................................................................................. 8

I. Recommendations......................................................................................................... 8
   A. Recommendation and Conclusion on Approvability............................................... 8
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable................................................................................................. 8

II. Summary of Chemistry Assessments ........................................................................... 8
   A. Description of the Drug Product(s) and Drug Substance(s)........................................ 8
   B. Description of How the Drug Product is Intended to be Used.................................... 8
   C. Basis for Approvability or Not-approval Recommendation........................................ 9

Chemistry Assessment .................................................................................................... 10
Chemistry Review Data Sheet

1. ANDA 201759

2. REVIEW #: 2

3. REVIEW DATE: March 23, 2011

4. REVIEWER: Richard Chang

5. PREVIOUS DOCUMENTS: N/A

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original submission</td>
<td>November 09, 2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>December 29, 2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>January 10, 2011</td>
</tr>
<tr>
<td>Gratuitous Amendment</td>
<td>January 13, 2011</td>
</tr>
<tr>
<td>Acceptable for filing</td>
<td>November 10, 2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>May 12, 2011</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

Name: Identi Pharmaceuticals Inc.
Address: 2224 W. Northern Ave.
         Suite# D-300
         Phoenix, Arisona 85021

          6333 Summercrest Drive
          Columbia, MD 21045
          Contact person: Jeanne Taborsky

8. DRUG PRODUCT NAME/CODE/TYPE:

   a) Proprietary Name: N/A
   Non-Proprietary Name (USAN): Fluocinolone Acetonide Oil 0.01 % Topical Oil
      (Scalp Oil)

9. LEGAL BASIS FOR SUBMISSION:
The Reference Listed Drug is Hill’s Derma-Smoother/FS® fluocinolone acetonide 0.01% Topical Oil (Scalp Oil) (NDA 019452)

PATENT CERTIFICATION STATEMENT

Identi Pharmaceuticals provided a statement of patent certification for the Abbreviated New Drug Application for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil).

Also presented is a marketing exclusivity statement required under 21 CFR Section 314.94(a)(3)(ii).

PATENT INFORMATION

Identi Pharmaceuticals’ proposed drug product is the generic version of Hill Dermaceuticals’ Derma-Smoother®, pursuant to NDA 019452. There are no unexpired patents for this drug product in the FDA listing titled Electronic Orange Book- Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as Orange Book). Identi Pharmaceuticals provided a Paragraph II certification for their drug product, Fluocinolone Acetonide Oil, 0.01%.

EXCLUSIVITY STATEMENT

The firm also provided an exclusivity statement to state that there is no unexpired exclusivity for this drug product.

10. PHARMACOL. CATEGORY:  
Glucocorticoid and indicated for the treatment of scalp psoriasis and atopic dermatitis in adults and for moderate to severe atopic dermatitis pediatric patients 2 years old and older.

11. DOSAGE FORM:  Topical Oil (Scalp Oil)

12. STRENGTH/POTENCY:  0.01%

13. ROUTE OF ADMINISTRATION: Topical

14. Rx/OTC DISPENSED:  ___Rx  ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):  
   _____SPOTS product – Form Completed
   ____x__Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:
   **Compendial name:** fluocinolone acetonide, USP
   **Chemical name:** Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-\{1-methylethylidene\}bis(oxy)\}--(6α,11β,16α)-6α,9-Difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone
   **Molecular formula:** C₂₄H₃₀F₂O₆ (anhydrous)
   **Molecular weight:** 452.50
   **Structure:**

![Chemical Structure]

17. RELATED/SUPPORTING DOCUMENTS:

**A. DMFs:**

<table>
<thead>
<tr>
<th>DMF #</th>
<th>Type</th>
<th>Item referenced</th>
<th>Holder</th>
<th>Code¹/ Status²</th>
<th>Date review completed</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1/Adequate</td>
<td>04/01/11</td>
<td>Reviewed by Richard Chang</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1 Action codes for DMF Table: 1 – DMF Reviewed. Other codes indicate why the DMF was not reviewed, as follows: 2 – Type 1 DMF; 3 – Reviewed previously and no revision since last review; 4 – Sufficient information in application; 5 – Authority to reference not granted; 6 – DMF not available; 7 – Other (explain under "Comments"); 2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents: N/A

18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>4/22/11</td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioequivalence</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Satisfactory (exclusion requested)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW

The application submission(s) covered by this review was taken in the date order of receipt.

_X___ Yes  ____ No  If no, explain reason(s) below:
The Chemistry Review for ANDA 201764

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on approvability

This ANDA is approvable (CMC). Labeling & Bio are pending.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if approvable

N/A

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Drug product
Fluocinolone Acetonide 0.01% Topical Oil contains fluocinolone acetonide which is a synthetic, fluorinated corticosteroid. It is intended for topical dermatologic use for the relief of the inflammatory and pruritic manifestation of atopic dermatitis in patients 1 year or older. Each gram of Fluocinolone Acetonide Oil, 0.01% contains 0.11 mg fluocinolone acetonide per mL in an oil consisting of isopropyl alcohol USP, refined peanut oil NF, isopropyl myristate NF, Oleth-2 and light mineral oil NF.

Fluocinolone Acetonide Oil, 0.01% is a clear, colorless to light straw colored liquid.
Fluocinolone acetonide oil will be marketed in the following package; 120 mL (4 oz) round bottle with a screw cap and a wrap around label. The product is placed in the carton with a white dispensing cap, medication guide and insert.

It is to be stored in controlled room temperature and shipped at cool or refrigerated conditions. The proposed expiration dating for the drug product is 24 months.

Drug substance
The chemical name of fluocinolone acetonide is Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-6α,9-Difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone. The drug substance is listed in the USP Monograph. It is a white to practically white crystalline powder. It is insoluble in water, freely soluble in acetone and glacial acetic acid, sparingly soluble in chloroform and methanol, and very slightly soluble in ether.

B. Description of How the Drug Product is Intended to be Used
Fluocinolone Acetonide Oil, 0.01%, should be applied to the affected area as a thin film three times daily for adult patients with atopic dermatitis and twice daily for up to four weeks for pediatric patients with atopic dermatitis.

Maximum daily dose (MDD) (the firm’s calculation option 1)
The MDD is calculated below based on the package insert information from Derma-Smoothe® Oil for Fluocinolone Acetonide Oil, 0.01% and 1 mL of oil can cover the affected area to form a thin film (See pages 27-28 of this review for more detailed discussion).

\[
\text{MDD} = \frac{\text{IT QT}}{\text{DS %}} \cdot \frac{\text{DP %}}{\text{IT QT}}
\]

<table>
<thead>
<tr>
<th></th>
<th>IT (%)</th>
<th>QT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DS</td>
<td>(b) (4)</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>DP</td>
<td>(b) (4)</td>
<td>(b) (4)</td>
</tr>
</tbody>
</table>

C. Basis for approvability or Not-approval Recommendation

The ANDA is approvable (CMC). Labeling & bioequivalence reviews are pending.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

-----------------------------------------------
RICHARD CHANG
05/26/2011

TRANG Q TRAN
05/26/2011

JAMES M FAN
05/26/2011
ANDA 201759

Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)

Identi Pharmaceuticals Inc.

Richard Chang
Chemistry I
# Table of Contents

Table of Contents .......................................................................................................................... 2

Chemistry Review Data Sheet ........................................................................................................ 3

The Executive Summary ................................................................................................................. 8

I. Recommendations ....................................................................................................................... 8
   A. Recommendation and Conclusion on Approvability ............................................................... 8
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable ........................................................................................................... 8

II. Summary of Chemistry Assessments ......................................................................................... 8
   A. Description of the Drug Product(s) and Drug Substance(s) ......................................................... 8
   B. Description of How the Drug Product is Intended to be Used ..................................................... 8
   C. Basis for Approvability or Not-approval Recommendation .......................................................... 9

Chemistry Assessment .................................................................................................................... 10
Chemistry Review Data Sheet

1. ANDA 201759

2. REVIEW #: 1

3. REVIEW DATE: March 15, 2011

4. REVIEWER: Richard Chang

5. PREVIOUS DOCUMENTS: N/A

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original submission</td>
<td>November 09, 2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>December 29, 2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>January 10, 2011</td>
</tr>
<tr>
<td>Gratuitous Amendment</td>
<td>January 13, 2011</td>
</tr>
<tr>
<td>Acceptable for filing</td>
<td>November 10, 2010</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

   Name: Identi Pharmaceuticals Inc.
   Address: 2224 W. Northern Ave.
             Suite# D-300
             Phoenix, Arisona 85021

             6333 Summercrest Drive
             Columbia, MD 21045
             Contact person: Jeanne Taborsky

8. DRUG PRODUCT NAME/CODE/TYPEx:

   a) Proprietary Name: N/A

   Non-Proprietary Name (USAN): Fluocinolone Acetonide Oil 0.01 % Topical Oil (Scalp Oil)

9. LEGAL BASIS FOR SUBMISSION:
The Reference Listed Drug is Hill’s Derma-Smoothe/FS® fluocinolone acetonide 0.01% Topical Oil (Scalp Oil) (NDA 019452)

**PATENT CERTIFICATION STATEMENT**

Identi Pharmaceuticals provided a statement of patent certification for the Abbreviated New Drug Application for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil).

Also presented is a marketing exclusivity statement required under 21 CFR Section 314.94(a)(3)(ii).

**PATENT INFORMATION**

Identi Pharmaceuticals’ proposed drug product is the generic version of Hill Dermaceuticals’ Derma-Smoothe®, pursuant to NDA 019452. There are no unexpired patents for this drug product in the FDA listing titled Electronic Orange Book- Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as Orange Book). Identi Pharmaceuticals provided a Paragraph II certification for their drug product, Fluocinolone Acetonide Oil, 0.01%.

**EXCLUSIVITY STATEMENT**

The firm also provided an exclusivity statement to state that there is no unexpired exclusivity for this drug product.

10. **PHARMACOL. CATEGORY:**
Glucocorticoid and indicated for the treatment of scalp psoriasis and atopic dermatitis in adults and for moderate to severe atopic dermatitis pediatric patients 2 years old and older.

11. **DOSAGE FORM:** Topical Oil (Scalp Oil)

12. **STRENGTH/POTENCY:** 0.01%

13. **ROUTE OF ADMINISTRATION:** Topical

14. **Rx/OTC DISPENSED:** __x_Rx ___OTC

15. **SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):**

_____SPOTS product – Form Completed

___x__Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

**Compendial name:** fluocinolone acetonide, USP

**Chemical name:** Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-6α,9-Difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone

**Molecular formula:** C$_{24}$H$_{30}$F$_2$O$_6$ (anhydrous)

**Molecular weight:** 452.50

**Structure:**

![Chemical Structure](image)

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>Type</th>
<th>Item referenced</th>
<th>Holder</th>
<th>Code$^1$/ Status$^2$</th>
<th>Date review completed</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (4)</td>
<td></td>
<td></td>
<td></td>
<td>1/Adequate</td>
<td>03/04/11</td>
<td>Reviewed by Richard Chang</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1 Action codes for DMF Table:  1 – DMF Reviewed.  
Other codes indicate why the DMF was not reviewed, as follows: 
2 – Type 1 DMF; 3 – Reviewed previously and no revision since last review; 4 – Sufficient information in application; 
5 – Authority to reference not granted; 6 – DMF not available; 7 – Other (explain under "Comments"); 2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents: N/A

18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioequivalence</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Satisfactory (exclusion requested)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW

The application submission(s) covered by this review was taken in the date order of receipt.

_X___ Yes    ____ No    If no, explain reason(s) below:
The Chemistry Review for ANDA 201764

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on approvability

This ANDA is presently non-approvable. The minor chemistry deficiency listed in the review should be addressed before the application can be approved. Labeling, Bio, and EES are pending.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if approvable

N/A

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

**Drug product**
Fluocinolone Acetonide 0.01% Topical Oil contains fluocinolone acetonide which is a synthetic, fluorinated corticosteroid. It is intended for topical dermatologic use for the relief of the inflammatory and pruritic manifestation of atopic dermatitis in patients 1 year or older. Each gram of Fluocinolone Acetonide Oil, 0.01% contains 0.11 mg fluocinolone acetonide per mL in an oil consisting of isopropyl alcohol USP, refined peanut oil NF, isopropyl myristate NF, Oleth-2 and light mineral oil NF.

Fluocinolone Acetonide Oil, 0.01% is a clear, colorless to light straw colored liquid. Fluocinolone acetonide oil will be marketed in the following package; 120 mL (4 oz) round bottle with a screw cap and a wrap around label. The product is placed in the carton with a white dispensing cap, medication guide and insert.

It is to be stored in controlled room temperature and shipped at cool or refrigerated conditions. The proposed expiration dating for the drug product is 24 months.

**Drug substance**
The chemical name of fluocinolone acetonide is Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-6α,9-Difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone. The drug substance is listed in the USP Monograph. It is a white to practically white crystalline powder. It is insoluble in water, freely soluble in acetone and glacial acetic acid, sparingly soluble in chloroform and methanol, and very slightly soluble in ether.
B. **Description of How the Drug Product is Intended to be Used**

Fluocinolone Acetonide Oil, 0.01%, should be applied to the affected area as a thin film three times daily for adult patients with atopic dermatitis and twice daily for up to four weeks for pediatric patients with atopic dermatitis.

Maximum daily dose (MDD) (Our calculation)
The MDD is calculated below based on the package insert information from Derma-Smoother Oil for Fluocinolone Acetonide Oil, 0.01% and ~2 mL of oil can cover the affected area to form a thin film.

\[
\text{MDD} = \text{IT QT} \%
\]

<table>
<thead>
<tr>
<th>DS</th>
<th>IT (%)</th>
<th>QT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DP</td>
<td>(\text{(b) (4)})</td>
<td>(\text{(b) (4)})</td>
</tr>
</tbody>
</table>

C. **Basis for approvability or Not-approval Recommendation**

The ANDA is non-approvable due to minor deficiencies. Labeling, bioequivalence reviews, and EES are pending.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RICHARD CHANG  
04/25/2011

TRANG Q TRAN  
04/26/2011

JAMES M FAN  
04/26/2011
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 201759

BIOEQUIVALENCE REVIEWS
Review of a Request for a Waiver of an In Vivo Bioequivalence Study Requirement

ANDA 201759

Drug Product: Fluocinolone Acetonide Topical Oil (Scalp Oil), 0.01%

Sponsor: Identi Pharmaceuticals, Inc.

Reference Drug: Derma-Smoothe/FS® (fluocinolone acetonide) Topical oil (for scalp use), NDA #019452 0.01%, approved November 9, 2005

Date of Submission: November 9, 2010

Reviewer: Nicole Lee, Pharm.D.

Identi Pharmaceuticals, Inc. requests a waiver of the in vivo bioequivalence study requirement for its generic fluocinolone acetonide topical oil (scalp oil), 0.01%. This product is a solution, and the sponsor’s proposed formulation is qualitatively (Q1), and quantitatively (Q2), the same (+5%) as the reference listed drug (RLD) for all components except for the two fragrance components, which were omitted from the sponsor’s proposed formulation. In an 8/20/2009 (finalized 9/8/2009) consult from The Division of Dermatology and Dental Products in the Office of New Drugs, it was determined that omission of the 2 fragrance components would not affect the safety and efficacy of a generic version of this product. The sponsor’s proposed formulation is acceptable for a waiver of the in vivo BE study requirements under 21 CFR § 320.22 (b)(1). A waiver is therefore granted. From a clinical bioequivalence perspective, this application is acceptable for approval.

Regulatory Background
The firm requests a waiver of in-vivo bioequivalence studies based on 21 CFR 320.22 (b)(3)(i-iii). This regulation states that a drug product’s in vivo bioavailability or bioequivalence may be considered self-evident based on other data in the application if the drug product is…(i) a solution for application to the skin…(ii) contains an active ingredient in the same concentration and dosage form as the drug product that is the subject of an approved full new drug application; AND (iii) contains no inactive ingredient or other change in formulation from the drug product that is the subject of the approved full new drug application that may significantly affect absorption of the active drug ingredient or active moiety for products that are systemically absorbed, or that may significantly affect systemic or local availability for products intended to act locally.

21 CFR 314.94(a)(9)(v) states that generally, a drug product intended for topical use…shall contain the same inactive ingredients as the reference listed drug identified by the applicant …However, an abbreviated application may include different inactive ingredients provided that the applicant identifies and characterizes the differences and

Reference ID: 3014873
provides information demonstrating that the differences do not affect the safety or efficacy of the proposed drug product.

Topical solutions may receive a waiver of *in-vivo* bioequivalence studies if the products are qualitatively and quantitatively the same or do not contain any inactive ingredients that may affect the safety and/or efficacy of the drug product.

Derma-Smoothe Body Oil, DermOtic Oil Ear Drops and Derma-Smoothe Scalp oil are approved in a single NDA 019452, although the FDA considers that they are separate products with unique labeling. Derma-Smoothe Body oil is indicated for atopic dermatitis. Derma-Smoothe Scalp oil is indicated for scalp psoriasis and is packaged with a shower cap. DermOtic Oil Ear Drops are indicated for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and older.

A waiver of a bioequivalence study was granted (Clinical Review dated 8/31/10) for this same sponsor’s ANDA 091306 Fluocinolone Acetonide 0.01% Oil Ear Drop which contains identical active and inactive ingredients as their proposed fluocinolone acetonide 0.01% scalp oil.

**Background**

The reference listed drug, Derma-Smoother/FS Oil (Scalp Oil), is a topical corticosteroid formulation indicated for treating psoriasis of the scalp in adult patients. It may be used for other conditions as determined by your doctor.

The product label provides the following directions for use of the product: Wet hair and scalp thoroughly before applying the medication. Apply a thin film to scalp and massage well. Cover the scalp with the shower cap provided for at least 4 hours or overnight. Afterwards, wash off the medication with regular shampoo and rinse well.

**Comparative Composition**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>TEST</th>
<th>RLD*</th>
<th>Proportional % Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluocinolone acetonide, USP</td>
<td>0.01</td>
<td>0.01</td>
<td>0</td>
</tr>
<tr>
<td>Isopropyl Alcohol, USP</td>
<td></td>
<td></td>
<td>*(b) (4)</td>
</tr>
<tr>
<td>Isopropyl Myristate, NF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oleth-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Light Mineral Oil, NF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refined Peanut Oil, NF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cream Fragrance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balsam Pine Fragrance</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*From NDA 19452
Excipient Function

<table>
<thead>
<tr>
<th>Excipient</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluocinolone acetonide, USP</td>
<td>Active</td>
</tr>
<tr>
<td>Isopropyl alcohol, USP</td>
<td></td>
</tr>
<tr>
<td>Isopropyl Myristate, NF</td>
<td></td>
</tr>
<tr>
<td>Oleth-2</td>
<td></td>
</tr>
<tr>
<td>Light Mineral Oil, NF</td>
<td></td>
</tr>
<tr>
<td>Refined Peanut Oil, NF</td>
<td></td>
</tr>
</tbody>
</table>

Conclusions

The formulation of the proposed product and the RLD are qualitatively identical and quantitatively very similar (within $\pm 5\%$) for all inactive ingredients except for omission of two fragrance ingredients. According to the 8/20/2009 consult from the Division of Dermatology and Dental Products, omission of the 2 fragrance components would not affect the safety and efficacy of the proposed generic product.

Recommendations

A waiver of the in vivo bioequivalence study requirement based on 21 CFR 320.22 (b)(3)(i-iii) is granted.

Nicole Lee, Pharm.D.
Clinical Reviewer
Division of Clinical Review

Dena R. Hixon, M.D.
Acting Director
Division of Clinical Review

Dale P. Conner, Pharm.D.
Director
Division of Bioequivalence I
BIOEQUIVALENCY DEFICIENCIES TO BE PROVIDED TO THE APPLICANT

ANDA: 201759  APPLICANT: Identi Pharmaceuticals, Inc.

DRUG PRODUCT: Fluocinolone Acetonide Topical Oil (Scalp Oil), 0.01%

The Division of Clinical Review has completed its review and has no further questions at this time.

Please note that the bioequivalency comments provided in this communication are preliminary. These comments are subject to revision after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling, or other scientific or regulatory issues. Please be advised that these reviews may result in the need for additional bioequivalency information and/or studies, or may result in a conclusion that the proposed formulation is not approvable.

Sincerely yours,

Dale P. Conner, Pharm.D.
Director, Division of Bioequivalence I
Office of Generic Drugs
Center for Drug Evaluation and Research

Reference ID: 3014873
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NICOLE LEE
09/14/2011

DENA R HIXON
09/14/2011
I concur.

DALE P CONNER
09/16/2011
### Summary of Findings by Division of Bioequivalence

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ]</td>
<td>Study meets statutory requirements N/A</td>
</tr>
<tr>
<td>[ ]</td>
<td>Study does NOT meet statutory requirements</td>
</tr>
<tr>
<td></td>
<td>Reason:</td>
</tr>
<tr>
<td>[x]</td>
<td>Waiver meets statutory requirements</td>
</tr>
<tr>
<td></td>
<td>Waiver does NOT meet statutory requirements</td>
</tr>
<tr>
<td></td>
<td>Reason:</td>
</tr>
</tbody>
</table>

### RECOMMENDATION:  
[ ] COMPLETE  
[ ] INCOMPLETE

Reviewed by:

_________________________  Date: ________________
Vipra Kundoor, Ph.D.  
Reviewer

_________________________  Date: ________________
April C. Braddy, Ph.D.  
Team Leader

_________________________  Date: ________________
Hoainhon N. Caramenico  
Acting Deputy Director
<table>
<thead>
<tr>
<th>Item Verified:</th>
<th>YES</th>
<th>NO</th>
<th>Required Amount</th>
<th>Amount Sent</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Assay Methodology</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Procedure SOP</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>☒</td>
<td>☐</td>
<td></td>
<td>N/A</td>
<td>Module 3.2.P.5.3</td>
</tr>
<tr>
<td>Study Results Ln/Lin</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>IRB Approval</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Dissolution Data</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Pre-screening of Patients</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Chromatograms</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Consent Forms</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Composition</td>
<td>☒</td>
<td>☐</td>
<td></td>
<td>N/A</td>
<td>Module 3.2.P.1</td>
</tr>
<tr>
<td>Summary of Study</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Individual Data &amp; Graphs, Linear &amp; Ln</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>PK/PD Data Disk Submitted)</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Randomization Schedule</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Protocol Deviations</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Clinical Site</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Analytical Site</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Study Investigators</td>
<td>☐</td>
<td>☒</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>
Additional Comments regarding the ANDA:

1. This is an electronic submission.

2. This is a First Generic application for Fluocinolone Acetonide Topical Oil (Scalp Oil), 0.01%.

3. The Reference Listed Drug (RLD) is Derma-Smoothe/FS® (fluocinolone acetonide) Topical Oil (Scalp Oil), 0.01% from Hill Dermac (NDA # 019452, initial approved on 03 February 1988 - Body Oil; approval for Scalp Oil (new indication)-approved date, 09 November 2005 – same formulation).¹

4. Derma-Smoothe/FS® (fluocinolone acetonide) Topical Oil (Scalp Oil), 0.01%, is a low to medium

¹ Drugs@FDA. Last accessed: 12/01/2010
potency corticosteroid indicated for the treatment of atopic dermatitis.  

5. Pursuant to 21 CFR § 320.22 (b) (3), the firm has submitted a request for a waiver of in vivo bioequivalence study requirements based on the qualitative (Q1) and quantitative (Q2) sameness between the test and RLD formulations.

6. The requirements for in-vivo testing may be waived as per 21 CFR 320.22 (b)(3) for Fluocinolone Acetonide Topical Oil, provided that the proposed drug product:

   (1) Is a solution for application to the skin

   (2) Contains an active ingredient in the same concentration and dosage form as the reference listed drug (RLD), Derma-Smoother/FS® (fluocinolone acetonide) Topical Oil, and

   (3) Contains no inactive ingredient or other change on formulation from the RLD that may significantly affect absorption of the active drug ingredient or active moiety.

The firm’s test formulation is provided below:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent (v/v)</th>
<th>Mg / mL (w/v)</th>
<th>batch (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluocinolone Acetonide, USP</td>
<td>0.01</td>
<td>0.010</td>
<td></td>
</tr>
<tr>
<td>Isopropyl Alcohol, USP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refined Peanut Oil, NF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oleth-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isopropyl Myristate, NF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mineral Oil, Light, NF</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Total                          | 100.00        | 100.00        |            |

The RLD formulation is provided below:

(NOT FOR RELEASE UNDER FOIA)

\(<http://www.accessdata.fda.gov/drugsatfda/docs(label/2005/019452s016,019,020lbl.pdf> \)

\(^3\) Controlled Document, Submission Date: May 05, 2004. Last accessed date: 12/01/2010.  
\(^4\) Electronic Document Room. ANDA # 201759. Module: 3.2.P.1

\(^5\) Archival Copy of NDA 019452; Volume 1.1. Date: August 14, 1985. Page 167.

\(^6\) DARRTS, NDA # 019452, REV-NONCLINICAL-03 (General Review), 06/13/2007. Last accessed date: 12/01/2010.

\(^7\) DARRTS, ANDA # 091306, FRM-ADMIN-44 (DBE Review Request), 06/30/2009. Last accessed date: 12/01/2010.
<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluocinolone Acetonide, USP</td>
<td>0.010</td>
</tr>
<tr>
<td>Refined peanut Oil, NF*</td>
<td></td>
</tr>
<tr>
<td>White Mineral Oil, USP</td>
<td></td>
</tr>
<tr>
<td>Oleth-2</td>
<td></td>
</tr>
<tr>
<td>Isopropyl Myristate, NF</td>
<td></td>
</tr>
<tr>
<td>Isopropyl Alcohol, NF</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Cream Fragrance</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Balsam Pine Fragrance</td>
<td>(b) (4)</td>
</tr>
</tbody>
</table>

Reference ID: 2872852
Percent (v/v) Difference in Inactive Ingredients between the Test and RLD Product

The differences in the active and inactive ingredients between the RLD and test product formulations are calculated below:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Test Formulation %v/v</th>
<th>Reference Product %v/v</th>
<th>% Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluocinolone Acetonide</td>
<td>0.01</td>
<td>0.01</td>
<td>0.0</td>
</tr>
<tr>
<td>Refined Peanut Oil</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Light Mineral Oil</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oleth-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isopropyl Alcohol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isopropyl Myristate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cream Fragrance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balsam Pine Fragrance</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The differences in the active and inactive ingredients between the RLD and test product formulations are calculated based on Q1 and Q2 comparison using %v/v. Difference = \([\text{RLD} - \text{Test}] / \text{RLD}\) * 100

7. The firm’s test product only differs from the RLD product in that it does not contain fragrances whereas the RLD product contains less than 4% volume/volume of fragrances. All other qualitatively (Q1) and quantitatively (Q2) differences in the formulation are within ± 5% based on the % volume/volume comparison of each of the inactive ingredients.

8. The Division of Bioequivalence (DBE) had previously submitted a clinical consult to the Clinical Division in the Office of Generic Drugs to request the clinical opinion on the safety and efficacy effect, if any, of the lack of fragrances in the test formulation, Fluocinolone Acetonide Oil, 0.01% (Ear Drops), ANDA # 091306.²

9. In a consult to the Division of Dermatology and Dental Products in the Office of New Drugs, it was determined that omission of the two fragrance components would not affect the safety and efficacy of the proposed generic product, Fluocinolone Acetonide Oil, 0.01% (Ear Drops), ANDA # 091306. The combined amount of these fragrance ingredients is only 4% of the total %v/v of the RLD product, DermOtic® Oil (fluocinolone acetonide oil) 0.01% Ear Drops.²

10. From a bioequivalence standpoint the application is acceptable for filing.

Additional Information Requested from the Applicant:

None.

---

### Completed Assignment for 201759 ID: 12715

**Reviewer:** Kundoor, Vipra  
**Date Completed:**  
**Verifier:**  
**Date Verified:**  
**Division:** Division of Bioequivalence  
**Description:**

<table>
<thead>
<tr>
<th>Productivity:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ID</strong></td>
</tr>
<tr>
<td>12715</td>
</tr>
</tbody>
</table>

Bean Total: 1
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

VIPRA R KUNDOOR  
12/06/2010

APRIL C BRADDY  
12/07/2010

HOAINHON N CARAMENICO on behalf of DALE P CONNER  
12/08/2010

Reference ID: 2872852
APPLICATION NUMBER:
ANDA 201759

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
Office of Generic Drugs  
Food and Drug Administration  
Center for Drug Evaluation and Research  
7620 Standish Place  
Rockville, MD 20855-2773  

November 15, 2011

RE: ANDA 201-759 Fluocinolone Acetonide Topical Oil 0.01% (Scalp Oil)  
eCTD 0008 Correspondence

Dear Sir/ Madam:

Pursuant to Code of Federal Regulations Title 21 §314.60, SciRegs International Inc., US Agent for Identi Pharmaceuticals, LLC, here within submits correspondence to our abbreviated new drug application (ANDA 201-759) for Fluocinolone Acetonide Topical Oil 0.01% (Scalp Oil).

Please be advised that there was a typographical error made to the filing form for the Applicant Information section, name of applicant. Identi Pharmaceuticals is a limited liability company (LLC) but was inadvertently listed an incorporation (Inc). Please address all future correspondence in relation to this ANDA to Identi Pharmaceuticals LLC.

This completes our submission. This submission is filed in eCTD format. A Letter of Non-Repudiation for SciRegs International Inc. has been submitted to the Agency under separate cover dated, February 1, 2008. Please contact C. Jeanne Taborsky, SciRegs International Inc. at phone (410) 309-3145; fax (410) 309-6145, if you have any questions concerning this submission.

Sincerely yours,

C. Jeanne Taborsky,  
US Regulatory Agent  
SciRegs International Inc.
## ROUTING SHEET

- **APPROVAL**
- **TENTATIVE APPROVAL**
- **SUPPLEMENTAL APPROVAL (NEW STRENGTH)**
- **CGMP**

**Division:** I  
**Team:** 13  
**PM:** Trang Tran

**ANDA #:201759**
**Firm Name:** Identi Pharmaceuticals Inc.
**ANDA Name:** Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil)
**RLD Name:** Smoothe/FS Topical Oil, 0.01% (Scalp Oil)

**Electronic AP Routing Summary Located:**
V:\Chemistry Division I\Team 13\Electronic AP Summary\201759.ARS.doc

**AP/TA Letter Located:**
V:\Chemistry Division I\Team 13\FIRMSAM\Identi\LTRS&RVS\201759.AP.DOC

**Project Manager Evaluation:**
- Date: 9/21/11  
  **Initials:** TT

- [x] Previously reviewed and tentatively approved --- Date ___
- [ ] Previously reviewed and CGMP Complete Response issued -- Date ___

<table>
<thead>
<tr>
<th>Original Rec’d date 11/09/10</th>
<th>Date of Application 11/09/10</th>
<th>Date Acceptable for Filing 11/10/10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patent Certification (type)</th>
<th>Date Patent/Excl. expires</th>
<th>N/A</th>
<th>Citizens’ Petition/Legal Case?</th>
<th>Yes</th>
<th>No</th>
<th>(If YES, attach email from PM to CP coord)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>First Generic</th>
<th>Yes</th>
<th>No</th>
<th>Priority Approval (Top 100, PEPFAR, etc.)?</th>
<th>Yes</th>
<th>No</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DMF#</th>
<th>(provide MF Jackets)</th>
<th>Prepared Draft Press Release sent to Cecelia Parise</th>
<th>Yes</th>
<th>No</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Suitability Petition/Pediatric Waiver</th>
<th>Pediatric Waiver Request:</th>
<th>Accepted</th>
<th>Rejected</th>
<th>Pending</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**EER Status:**
- [ ] Pending  
- [x] Acceptable  
- OAI  
**EES Date Acceptable:** 8/10/11  
**Warning Letter Issued; Date:**
**Has there been an amendment providing for a Major change in formulation since filling?**
- Yes | No  
**Comment:**
**Date of Acceptable Quality (Chemistry) 10/13/11**
**Addendum Needed:**
- Yes | No  
**Comment:**
**Date of Acceptable Bio 9/16/11**
**Bio reviews in DARRTS:**
- Yes | No  
**(Volume location: )**
**Date of Acceptable Labeling 10/12/11**
**Attached labeling to Letter:**
- Yes | No  
**Comment:**
**Date of Acceptable Sterility Assurance (Micro) N/A**

**Methods Val. Samples Pending:**
- Yes | No  
**Commitment Rcvd. from Firm:**
- Yes | No  

**Post Marketing Agreement (PMA):**
- Yes | No  
**(If yes, email PM Coordinator)  
**Comment:**

**Modified-release dosage form:**
- Yes | No  
**(If yes, enter dissolution information in Letter)  
**

**Routing:**
- **Labeling Endorsement, Date emailed:**  
  REMS Required:  
  REMS Acceptable:  
  REMS Required:  
**Regulatory Support**
**Paragraph 4 Review (Dave Read, Susan Levine), Date emailed:**
**Division**
**1st Generic Review**
**Bob West / Peter Rickman**
**Keith Webber**

**Filed AP Routing Summary in DARRTs**
**Notified Firm and Faxed Copy of Approval Letter**
**Sent Email to "CDER-OGDAPPROVALS" distribution list**

Reference ID: 3030038
## Regulatory Support Branch Evaluation

**Martin Shimer**  
Chief, Reg. Support Branch

<table>
<thead>
<tr>
<th>Contains GDEA certification:</th>
<th>Yes ☑ No ☐</th>
<th>Determin. of Involvement?</th>
<th>Yes ☑ No ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>(required if sub after 6/1/92)</td>
<td></td>
<td>Pediatric Exclusivity System</td>
<td></td>
</tr>
<tr>
<td>Patent/Exclusivity Certification:</td>
<td>Yes ☑ No ☐</td>
<td>RLD = ☐ NDA# ☐</td>
<td></td>
</tr>
<tr>
<td>If Para. IV Certification- did applicant:</td>
<td>Yes ☐ No ☑</td>
<td>Date Checked</td>
<td></td>
</tr>
<tr>
<td>Notify patent holder/NDA holder</td>
<td>Yes ☑ No ☐</td>
<td>Nothing Submitted</td>
<td>☐</td>
</tr>
<tr>
<td>Was applicant sued w/in 45 days:</td>
<td>Yes ☑ No ☐</td>
<td>Written request issued</td>
<td>☐</td>
</tr>
<tr>
<td>Has case been settled:</td>
<td>Yes ☑ No ☐</td>
<td>Study Submitted</td>
<td>☐</td>
</tr>
<tr>
<td>Date settled:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is applicant eligible for 180 day</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Generic Drugs Exclusivity for each strength: Yes ☑ No ☐  
Date of latest Labeling Review/Approval Summary:  
Any filing status changes requiring addition Labeling Review: Yes ☑ No ☐  
Type of Letter: ☑ APPROVAL ☐ TENTATIVE APPROVAL ☐ SUPPLEMENTAL APPROVAL (NEW STRENGTH) ☐ CGMP  
OTHER: ☐

Comments: ANDA submitted on 11/10/2010, BOS=Derma-Smoothe/FS Scalp Oil NDA 19452, PII cert provided. ANDA ack for filing on 11/10/2010 (LO dated 2/16/2011). There are no remaining unexpired patents or exclusivities which protect the RLD. This ANDA is eligible for immediate Full Approval.

## Labeling Endorsement

Reviewer, :  
Labeling Team Leader, :  
Date _____  
Initials _____  
Date _____  
Initials _____

REMS required? ☑ Yes ☐ No  
REMS acceptable? ☑ Yes ☐ No ☐ n/a

Comments:

## Paragraph IV Evaluation

**David Read**  
OGD Regulatory Counsel

Pre-MMA Language included ☐  
Post-MMA Language Included ☐  
Comments:

## Quality Division Director /Deputy Director Evaluation

Chemistry Div. I (Raw)  
Comments: CMC Approvable

## First Generic Evaluation

**Frank Holcombe**  
Assoc. Dir. For Chemistry

Comments: (First generic drug review)

## OGD Office Management Evaluation

**Peter Rickman**  
Date 10/17/2011

Reference ID: 3030038
Comments: BOS=Derma-Smoother/FS Scalp Oil NDA 19452, applicant provided a PII patent cert. there are no remaining unexpired patents or exclusivities which protect the RLD. chemistry acceptable 9/16/2011. bio acceptable 9/16/2011 (waiver granted). labeling acceptable 10/12/2011. EER acceptable 8/10/2011. This ANDA is eligible for immediate Full Approval.

AND/OR

7. **Robert L. West**
   Deputy Director, OGD
   Para.IV Patent Cert: Yes □ No ☐
   Pending Legal Action: Yes □ No ☐
   Petition: Yes ☐ No □
   Press Release Acceptable □
   Date PETS checked for first generic drug ______

   Comments:

8. **OGD Director Evaluation**
   Keith Webber
   Deputy Director, OPS
   Comments:
   First Generic Approval □
   PD or Clinical for BE □
   Special Scientific or Reg.Issue □
   Press Release Acceptable □

   Comments:

9. **Project Manager**
   Date 10/17/11
   Initials TT
   Check Communication and Routing Summary into DARRTS
DARRTS Application History:
Orange Book Report:
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

TRANG Q TRAN
10/17/2011
TO: Identi Pharmaceuticals, LLC.
ATTN: Jeanne Taborsky
FROM: Beverly Weitzman

This facsimile is in reference to your abbreviated new drug application submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Fluocinonide Acetonide Oil (Scalp Oil)

Pages (including cover): 3

SPECIAL INSTRUCTIONS:

Effective 01-Aug-2010, the new mailing address for Abbreviated New Drug Application (ANDA) Regulatory Documents has become:

Office of Generic Drugs
Document Control Room
7620 Standish Place
Rockville, Maryland 20855

ANDAs will only be accepted at the new mailing address listed above. For further information, please refer to the following websites prior to submitting your ANDA Regulatory documents: Office of Generic Drugs (OGD): http://www.fda.gov/cder/ogd or Federal Register: http://www.gpoaccess.gov/fr/

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, OR PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.

If received by someone other than the addressee or a person authorized to deliver this document to the addressee, you are hereby notified that any disclosure, dissemination, copying, or other action to the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us by mail at the above address.
ANDA Number: 201759
Date of Submission: November 9, 2010 and May 12, 2011
Applicant's Name: Identi Pharmaceuticals, LLC.
Established Name: Fluocinolone Acetonide Oil, 0.01% (Scalp Oil)

Labeling Comments:

1. CONTAINER: Satisfactory in DRAFT.
2. CARTON: Satisfactory in DRAFT.
3. INSERT: Satisfactory in Final Print.

Submit final printed labeling electronically.
Prior to approval, it may be necessary to revise your labeling subsequent to approved changes for the reference listed drug. In order to keep ANDA labeling current, we suggest that you subscribe to the daily or weekly updates of new documents posted on the CDER web site at the following address -
http://service.govdelivery.com/service/subscribe.html?code=USFDA_17

{See appended electronic signature page}
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOHN F GRACE
10/12/2011
for Wm Peter Rickman
RE: ANDA 201-759 Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)
eCTD 0007 Labeling Amendment – Final Printed Labeling

Dear Sir/ Madam:

Pursuant to *Code of Federal Regulations* Title 21 § 314.96, SciRegs International Inc., US Agent for Identi Pharmaceuticals, LLC, here within submits a labeling amendment to our abbreviated new drug application (ANDA 201-759) for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil). On October 7, 2011, Identi received the following telephone deficiency (by e-mail) from Beverly Weitzman, Labeling Reviewer, Office of Generic Drugs:

1. *Please provide final printed labeling.*

   The final printed bottle and carton labels are included in Section 1.14.2.1 Final Labels. The Final Printed Label version of the insert us provided in Section 1.14.2.2 Final Package Insert. The SPL labeling has also been provided in Section 1.14.2.3 Final Label Text.

This completes our submission. This submission is filed in eCTD format. A Letter of Non-Repudiation for SciRegs International Inc. has been submitted to the Agency under separate cover dated, February 1, 2008. Please contact C. Jeanne Taborsky, SciRegs International Inc. at phone (410) 309-3145; fax (410) 309-6145, if you have any questions concerning this submission.

Sincerely yours,

C. Jeanne Taborsky,
US Regulatory Agent
SciRegs International Inc.
RE: ANDA 201-759 Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)  
eCTD 0006 Telephone Amendment

Dear Sir/ Madam:

Pursuant to Code of Federal Regulations Title 21 § 314.96, SciRegs International Inc., US Agent for Identi Pharmaceuticals, LLC, here within submits a telephone amendment to our abbreviated new drug application (ANDA 201-759) for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil). On September 26, 2011, Identi received the following telephone deficiency (by e-mail) from Richard D. Chang Chemistry Reviewer, Office of Generic Drugs:

1. Please remove the following tests and specifications from your drug product release and stability specifications:

Please submit a revised drug product release and stability specifications.

As requested, Identi removed the following tests and specifications from our drug product release and stability specifications:

and submitted revised drug product release specifications in Section 3.2.P.5.1 Specifications and stability specifications in Section 3.2.P.8.1 Stability. The method for related compounds and assay has also been revised to reflect the changes to the impurities reporting. The revised method 701-AS-RC is provided herein.

This completes our submission. This submission is filed in eCTD format. A Letter of Non-Repudiation for SciRegs International Inc. has been submitted to the Agency under separate cover dated, February 1, 2008. Please contact C. Jeanne Taborsky, SciRegs International Inc. at phone (410) 309-3145; fax (410) 309-6145, if you have any questions concerning this submission.

Sincerely yours,

C. Jeanne Taborsky,
US Regulatory Agent
SciRegs International Inc.
BIOEQUIVALENCY COMMENTS

ANDA 201759

OFFICE OF GENERIC DRUGS, CDER, FDA
Document Control Room, Metro Park North VII
7620 Standish Place
Rockville, MD  20855

APPLICANT:  Identi Pharmaceuticals Inc.
ATTN:  C. Jeanne Taborsky
President & CEO
FROM:  Nitin K. Patel

Dear Madam:

This facsimile is in reference to the bioequivalency data submitted on November 9, 2010, pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Fluocinolone Acetonide Topical Oil (Scalp Oil), 0.01%.

The Division of Bioequivalence has completed its review of the submission(s) referenced above and has provided comments which are presented on the attached 1 page.  This facsimile is to be regarded as an official FDA communication and unless requested, a hard-copy will not be mailed.

Please direct any questions concerning this communication to the Project Manager identified above.

SPECIAL INSTRUCTIONS:

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, OR PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.

If received by someone other than the addressee or a person authorized to deliver this document to the addressee, you are hereby notified that any disclosure, dissemination, copying, or other action to the content of this communication is not authorized.  If you have received this document in error, please immediately notify us by telephone and return it to us by mail at the above address.
BIOEQUIVALENCY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 201759  APPLICANT: Identi Pharmaceuticals, Inc.

DRUG PRODUCT: Fluocinolone Acetonide Topical Oil (Scalp Oil), 0.01%

The Division of Clinical Review has completed its review and has no further questions at this time.

Please note that the bioequivalency comments provided in this communication are preliminary. These comments are subject to revision after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling, or other scientific or regulatory issues. Please be advised that these reviews may result in the need for additional bioequivalency information and/or studies, or may result in a conclusion that the proposed formulation is not approvable.

Sincerely yours,

{See appended electronic signature page}

Dale P. Conner, Pharm.D.
Director, Division of Bioequivalence I
Office of Generic Drugs
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NITIN K PATEL
09/19/2011

DALE P CONNER
09/21/2011
Office of Generic Drugs  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Document Control Room  
7620 Standish Place  
Rockville, MD 20855-2773  

August 22, 2011

RE: ANDA 201-759 Fluocinolone Acetonide Oil 0.01% Scalp Oil  
eCTD 0005 Telephone Amendment

Dear Sir/ Madam:

Pursuant to Code of Federal Regulations Title 21 § 314.96, SciRegs International Inc., US Agent for Identi Pharmaceuticals, LLC, here within submits a Telephone Amendment to our abbreviated new drug application (ANDA 201-759) for Fluocinolone Acetonide Oil 0.01% Body Oil.

On August 9, 2011, Identi received the following telephone deficiency (by e-mail) from Richard Chang, Chemistry Reviewer, Office of Generic Drugs for our abbreviated new drug application (ANDA 091-306) for Fluocinolone Acetonide Oil 0.01% Ear Drops:

“This is in reference to your ANDA 091306 Gratuitous Amendment dated June 08, 2011. Please submit a test method verification report by Amneal for API impurities determination using the supplier's test method.”

On August 18, 2011, we submitted the requested information to ANDA 091-306. Since the same information is submitted to the sister ANDA 201-759 Fluocinolone Acetonide Oil 0.01% Scalp Oil and ANDA 201-764 Fluocinolone Acetonide Oil 0.01% Body Oil, we contacted Richard Chang and were instructed to submit the same information to the sister ANDAs.

As requested, Identi is herein providing a copy of the method verification report and the respective test method.

This completes our submission. This submission is filed in eCTD format. A Letter of Non-Repudiation for SciRegs International Inc. has been submitted to the Agency under separate cover dated, February 1, 2008. Please contact C. Jeanne Taborsky, SciRegs International Inc. at phone (410) 309-3145; fax (410) 309-6145, if you have any questions concerning this submission.

Sincerely yours,

C. Jeanne Taborsky,  
US Regulatory Agent  
SciRegs International Inc.
Dear Sir/ Madam:

Pursuant to Code of Federal Regulations Title 21 § 314.96, SciRegs International, Inc., US Agent for Identi Pharmaceuticals, LLC, here within submits a minor amendment to our abbreviated new drug application (ANDA) for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil). Reference is made to Identi’s Original Submission eCTD 0000, submitted November 9, 2010, telephone amendment eCTD 0002 submitted, January 10, 2011, and the gratuitous amendment eCTD 0003 submitted, January 13, 2011.

The agency deficiencies and Identi’s responses are as follows:

A. Deficiencies:

1. **The specification for Oleth-2 Microbiological limit in the Module 2 is not correct (i.e., Please revise.**

   As requested we have corrected the typo in Module 2 Section 2.3.P.4 Excipients Table 17 for the limit for Oleth-2. A revised copy of Module 2.3.P.4 Drug Product: Excipients is provided in pdf and word formats.

2. **As the Oleth-2 and Refined Peanut Oil, NF are considered critical to the stability and safety of your drug product, we request a commitment that a prior approval supplement will be submitted if the supplier and/or grade of these materials are changed.**

   Identi commits to file a prior approval supplement to the ANDA in the event that a change in supplier or material grade is made for the Oleth-2 or the Refined Peanut Oil, NF.

3. **Please provide your calculation of the maximum daily dose for your drug product and tighten your drug product release and stability specifications for Individual Unspecified Impurities, according to the maximum daily dose and ICH Q3B.**
As requested, the calculation for maximum daily dose of the drug product is provided in Section 3.2.P.5.6 Justification of Specifications. The MDD is less than 1 mg per day; therefore, the currently proposed limits for this product meet the ICH limits.

After due consideration, Identi is also responding to the following deficiencies that were listed in the letter for ANDA 201-764 Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) but omitted in the deficiency letter for this ANDA:

The table to which you are referring lists the vendors, not the manufacturers. On this table the vendor is correctly listed and the vendor does not have a DMF. However to alleviate confusion, Identi has revised Module 2 Section 2.3.P.7 Table 22 Component Vendors to be Component Manufacturers and added the DMF number for the manufacturer.

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comments in your response:

1. Please provide all available drug product room temperature stability data.

As requested, all drug product room temperature stability data available to date is provided in Module 3 Section 3.2.P.8.3 Stability Data to Date.

2. Bioequivalency and labeling information you have provided is pending review. After the reviews are completed, any deficiencies found will be communicated to you separately.

Identi notes and acknowledges that the bioequivalence and labeling reviews are pending review from their respective departments, and that we will be notified via separate communication of any deficiencies.
3. All facilities referenced in your ANDA should be in compliance with cGMP at the time of approval. We have requested an evaluation from the Office of Compliance.

The facilities referenced in ANDA 201-759 Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) that are subject to inspection have been inspected for this product in the inspection for ANDA 91-306 Fluocinolone Acetonide 0.01% Topical Oil within the last two years and are in compliance with current GMPs.

This completes our submission. This ANDA is filed in eCTD format. A Letter of Non-Repudiation for SciRegs International Inc. has been submitted to the Agency under separate cover dated, February 1, 2008. Please contact C. Jeanne Taborsky, SciRegs International Inc. at phone (410) 309-3145; fax (410) 309-6145, if you have any questions concerning this submission.

Sincerely yours,

C. Jeanne Taborsky,
US Regulatory Agent
SciRegs International Inc.
QUALITY DEFICIENCY - MINOR

ANDA  201759

OFFICE OF GENERIC DRUGS, CDER, FDA
Document Control Room, Metro Park North VII
7620 Standish Place
Rockville, Maryland 20855

APPLICANT:  Identi Pharmaceuticals Inc.  TEL: (410) 309-3145
ATTN:  C. Jeanne Taborsky  FAX: (410) 309-6145
FROM:  Trang Q. Tran  FDA CONTACT PHONE: (240) 276-8518

Dear Madam:

This facsimile is in reference to your abbreviated new drug application dated November 9, 2010, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil).

The Division of Chemistry has completed its review of the submission(s) referenced above and has identified deficiencies which are presented on the attached 2 pages. This facsimile is to be regarded as an official FDA communication and unless requested, a hard copy will not be mailed.

Your amendment should respond to all of the deficiencies listed. Facsimiles or partial replies will not be considered for review, nor will the review clock be reactivated until all deficiencies have been addressed. The response to this facsimile will be considered to represent a MINOR AMENDMENT and will be reviewed according to current OGD policies and procedures. Your cover letter should clearly indicate that the response is a QUALITY MINOR AMENDMENT / RESPONSE TO INFORMATION REQUEST and should appear prominently in your cover letter.

We also request that you include a copy of this communication with your response. Please direct any questions concerning this communication to the project manager identified above.

SPECIAL INSTRUCTIONS:

Effective **01-Aug-2010**, the new mailing address for Abbreviated New Drug Application (ANDA) Regulatory Documents will be:

Office of Generic Drugs, CDER, FDA
Document Control Room, Metro Park North VII
7620 Standish Place
Rockville, Maryland 20855

All ANDA documents will only be accepted at the new mailing address listed above. For further information, please refer to the following websites prior to submitting your ANDA Regulatory documents: Office of Generic Drugs (OGD): [http://www.fda.gov/cder/ogd](http://www.fda.gov/cder/ogd) or Federal Register: [http://www.gpoaccess.gov/fr/](http://www.gpoaccess.gov/fr/)

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, OR PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.

If received by someone other than the addressee or a person authorized to deliver this document to the addressee, you are hereby notified that any disclosure, dissemination, copying, or other action to the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us by mail at the above address.
CHEMISTRY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 201759                          APPLICANT: Identi Pharmaceuticals Inc.

DRUG PRODUCT: Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)

The deficiencies presented below represent MINOR deficiencies.

A. Deficiency:
   1. The specification for Oleth-2 Microbiological limit in the Module 2 is not correct (i.e., [b](4) Please revise.
   2. As the Oleth-2 and Refined Peanut Oil, NF are considered critical to the stability and safety of your drug product, we request a commitment that a prior approval supplement will be submitted if the supplier and/or grade of these materials are changed.
   3. 
   4. Please provide your calculation of the maximum daily dose for your drug product and tighten your drug product release and stability specifications for Individual Unspecified Impurities, according to the maximum daily dose and ICH Q3B.

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comments in your response:
   1. Please provide all available drug product room temperature stability data.
   2. Bioequivalency and labeling information you have provided is pending review. After the reviews are completed, any deficiencies found will be communicated to you separately.
3. All facilities referenced in your ANDA should be in compliance with cGMP at the time of approval. We have requested an evaluation from the Office of Compliance.

Sincerely yours,

{See appended electronic signature page}

Paul Schwartz, Ph.D.
Acting Director
Division of Chemistry I
Office of Generic Drugs
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JAMES M FAN
04/26/2011
for Paul Schwartz
OFFICE OF GENERIC DRUGS EXPEDITED REVIEW REQUESTED

ANDA/SUPPLEMENT #: 201759  APPLICANT: Identi Pharmaceuticals Inc.
DRUG: Fluocinolone Acetonide Topical Oil (scalp) 0.01%
DATE OF SUBMISSION: November 9, 2010

The Office of Generic Drugs MaPP # 5240.1 lists the following criteria for granting expedited review status to a supplemental abbreviated new drug application. At least one of the criteria must be met.

1. PUBLIC HEALTH NEED. Events that affect the availability of a drug for which there is no alternative

2. EXTRAORDINARY HARDSHIP ON THE APPLICANT.

   a) Catastrophic events such as explosion, fire storms damage.

   b) Events that could not have been reasonably foreseen and for which the applicant could not plan. Examples include:

      ♦ Abrupt discontinuation of supply of active ingredient, packaging material, or container closure; and
      ♦ Relocation of a facility or change in an existing facility because of a catastrophic event (see item 2a)

3. AGENCY NEED.

   a) Matters regarding the government’s drug purchase program, upon request from the appropriate FDA office.

   b) Federal or state legal/regulatory actions, including mandated formation changes or labeling changes if it is in the Agency’s best interest.

   c) Expiration-date extension or packaging change when the drug product is the subject of a government contract award.

   d) Request for approval of a strength that was previously tentatively approved (To be used in those cases where 180-day generic drug exclusivity prevented full approval of all strengths).

RECOMMENDATIONS:

<table>
<thead>
<tr>
<th>DISCIPLINE</th>
<th>STATUS</th>
<th>SIGNATURE/DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Team Project Manager (PM must Endorse)</td>
<td>Grant ✗</td>
<td>Deny ☑</td>
</tr>
<tr>
<td>Chemistry Team Leader (sign as needed)</td>
<td>Grant ✗</td>
<td>Deny ☑</td>
</tr>
<tr>
<td>Micro Team Leader (sign as needed)</td>
<td>Grant ✗</td>
<td>Deny ☑</td>
</tr>
<tr>
<td>Labeling Team Leader (sign as needed)</td>
<td>Grant ✗</td>
<td>Deny ☑</td>
</tr>
<tr>
<td>Chem. Div./Deputy Director (DO must Endorse)</td>
<td>Grant ✗</td>
<td>Deny ☑</td>
</tr>
</tbody>
</table>

RETURN TO PROJECT MANAGER CHEMISTRY TEAM: Trang Tran
a) When expedited review is denied, notify the applicant by telephone

ENTER FORM INTO DFS
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

TIMOTHY G JETTON
02/14/2011

MARTIN H Shimer
03/04/2011
ANDA CHECKLIST FOR CTD or eCTD FORMAT
FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING

*For a Comprehensive Table of Contents Headings and Hierarchy please go to:  http://www.fda.gov/cder/regulatory/ersr/5640CTOC-v1.2.pdf
** For more CTD and eCTD informational links see the final page of the ANDA Checklist
*** A model Quality Overall Summary for an immediate release tablet and an extended release capsule can be found on the OGD webpage http://www.fda.gov/cder/ogd/ ***

ANDA #: 201759    FIRM NAME: IDENTI PHARMACEUTICALS INC.
PIV: NO    Electronic or Paper Submission: GATEWAY (ELECTRONIC DATA)

RELATED APPLICATION(S):  91-306 FROM IDENTI PHARMACEUTICALS INC. FOR FLUOCINOLONE ACETONIDE OIL, 0.01% (EAR DROPS) RLD: DERMOTIC OIL
First Generic Product Received? NO

DRUG NAME: FLUOCINOLONE ACETONIDE
DOSAGE FORM: TOPICAL 0.01%

Review Team: (Bolded/Italicized & Checked indicate Assignment or DARRTS designation)

Quality Team: DCI TM 13
☑ Activity
ANDA/Quality RPM: Tran Trang ☑ FYI
Quality Team Leader: Tran Trang
No assignment needed in DARRTS
Labeling Reviewer: Beverly Weitman ☑ Activity

Bio Team 10: April Braddy
☑ Activity
Bio PM: Diana Solana
Clinical Endpoint Team Assignment: (No) ☐ Activity
Micro Review (No) ☐ Activity

***Document Room Note: for New Strength amendments and supplements, if specific reviewer(s) have already been assigned for the original, please assign to those reviewer(s) instead of the default random team(s). ***

Letter Date: NOVEMBER 9, 2010    Received Date: NOVEMBER 10, 2010
Comments: EC-1 YES    On Cards: YES
Therapeutic Code: 4025010 CORTICOSTEROIDS

Archival copy: GATEWAY (ELECTRONIC DATA)    Sections I
Review copy: NA E-Media Disposition: NA
Not applicable to electronic sections

PART 3 Combination Product Category  N Not a Part3 Combo Product
(Must be completed for ALL Original Applications) Refer to the Part 3 Combination Algorithm

Reviewing CSO/CST    Tim Jetton
Date

Recommendation:
☐ FILE    ☐ REFUSE to RECEIVE

Reference ID: 2904915
1. Edit Application Property Type in DARRTS where applicable for
   a. First Generic Received
      □ Yes  ✔ No
   b. Market Availability
      ✔ Rx  □ OTC
   c. Pepfar
      □ Yes  □ No
   d. Product Type
      □ Small Molecule Drug (usually for most ANDAs except protein drug products)
      □ Yes  □ No
2. Edit Submission Patent Records
   ✔ Yes
3. Edit Contacts Database with Bioequivalence Recordation where applicable
   □ Yes
4. Requested EER
   □ Yes

ADDITIONAL COMMENTS REGARDING THE ANDA:

1. Jeanne Taborsky 410-309-3145
2. Need sec 2.3 in WORD – sent in 1/10/11
3. COA for finished product has no lot number on it? – sent in 1/10/11

---

**MODULE 1**

**ADMINISTRATIVE**

| 1.1 | 1.1.2 Signed and Completed Application Form (356h) (original signature)  
(Check Rx/OTC Status) RX YES |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.2</td>
<td>Cover Letter  Dated: NOVEMBER 9, 2010</td>
<td>✔</td>
</tr>
<tr>
<td>1.2.1</td>
<td>Form FDA 3674 <em>(PDF)</em> YES – box a</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Table of Contents (paper submission only) YES</td>
<td>✔</td>
</tr>
<tr>
<td>1.3.2</td>
<td>Field Copy Certification (original signature) NA</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>(N/A for E-Submissions)</td>
<td>✔</td>
</tr>
<tr>
<td>1.3.3</td>
<td>Debarment Certification-GDEA (Generic Drug Enforcement Act)/Other:</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>1. Debarment Certification (original signature) YES</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>2. List of Convictions statement (original signature) YES</td>
<td>✔</td>
</tr>
<tr>
<td>1.3.4</td>
<td>Financial Certifications</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Bioavailability/Bioequivalence Financial Certification (Form FDA 3454) NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disclosure Statement (Form FDA 3455, submit copy to Regulatory Branch Chief) NO</td>
<td></td>
</tr>
</tbody>
</table>
1.3.5 1.3.5.1 Patent Information
Patents listed for the RLD in the Electronic Orange Book Approved Drug Products with
Therapeutic Equivalence Evaluations

1.3.5.2 Patent Certification
1. Patent number(s) na
2. Paragraph: (Check all certifications that apply)
   MOU [ ] PI [ ] PII [ ] PIII [ ]
   PIV [ ] (Statement of Notification) [ ]
3. Expiration of Patent(s): NA
   a. Pediatric exclusivity submitted?
   b. Expiration of Pediatric Exclusivity?
4. Exclusivity Statement: YES

1.4.1 References
Letters of Authorization
1. DMF letters of authorization
   a. Type II DMF authorization letter(s) or synthesis for Active Pharmaceutical
      Ingredient yes
      Type II DMF No [b][d]
   b. Type III DMF authorization letter(s) for container closure yes
2. US Agent Letter of Authorization (U.S. Agent [if needed, countersignature
   on 356h]) yes

1.12.11 Basis for Submission
NDA# : 19-452
Ref Listed Drug: DERMA-SMOOTHE/FS
Firm: HILL DERMACEUTICALS INC.
ANDA suitability petition required? NA
If Yes, then is change subject to PREA (change in dosage form, route or active ingredient)
see section 1.9.1

MODULE 1 (Continued)
ADMINISTRATIVE

1.12.12 Comparison between Generic Drug and RLD-505(j)(2)(A)
1. Conditions of use yes
2. Active ingredients yes
3. Inactive ingredients yes
4. Route of administration yes
5. Dosage Form yes
6. Strength yes

1.12.14 Environmental Impact Analysis Statement YES

1.12.15 Request for Waiver
Request for Waiver of In-Vivo BA/BE Study(ies): YES

1.14.1 Draft Labeling (Mult Copies N/A for E-Submissions)
1.14.1.1 4 copies of draft (each strength and container) yes
1.14.1.2 1 side by side labeling comparison of containers and carton with all
differences annotated and explained yes
1.14.1.3 1 package insert (content of labeling) submitted electronically yes
***Was a proprietary name request submitted?
(If yes, send email to Labeling Reviewer indicating such.)

Reference ID: 2904915
<table>
<thead>
<tr>
<th>1.14.3</th>
<th>Listed Drug Labeling</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.14.3.1</strong></td>
<td>1 side by side labeling (package and patient insert) comparison with all differences annotated and explained  yes</td>
</tr>
<tr>
<td><strong>1.14.3.3</strong></td>
<td>1 RLD label and 1 RLD container label  yes</td>
</tr>
</tbody>
</table>
2.3

Quality Overall Summary (QOS)
- E-Submission: PDF yes
  - Word Processed e.g., MS Word

A model Quality Overall Summary for an immediate release tablet and an extended release capsule can be found on the OGD webpage http://www.fda.gov/cder/ogd/

Question based Review (QbR) no

2.3.S

Drug Substance (Active Pharmaceutical Ingredient) yes
  - 2.3.S.1 General Information
  - 2.3.S.2 Manufacture
  - 2.3.S.3 Characterization
  - 2.3.S.4 Control of Drug Substance
  - 2.3.S.5 Reference Standards or Materials
  - 2.3.S.6 Container Closure System
  - 2.3.S.7 Stability

2.3.P

Drug Product yes
  - 2.3.P.1 Description and Composition of the Drug Product
  - 2.3.P.2 Pharmaceutical Development
    - 2.3.P.2.1 Components of the Drug Product
      - 2.3.P.2.1.1 Drug Substance
      - 2.3.P.2.1.2 Excipients
    - 2.3.P.2.2 Drug Product
    - 2.3.P.2.3 Manufacturing Process Development
    - 2.3.P.2.4 Container Closure System
  - 2.3.P.3 Manufacture
  - 2.3.P.4 Control of Excipients
  - 2.3.P.5 Control of Drug Product
  - 2.3.P.6 Reference Standards or Materials
  - 2.3.P.7 Container Closure System
  - 2.3.P.8 Stability

2.7

Clinical Summary (Bioequivalence)
Model Bioequivalence Data Summary Tables
- E-Submission: PDF
  - Word Processed e.g., MS Word

2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
  - 2.7.1.1 Background and Overview
    - Table 1. Submission Summary
    - Table 4. Bioanalytical Method Validation
    - Table 6. Formulation Data
  - 2.7.1.2 Summary of Results of Individual Studies
    - Table 5. Summary of In Vitro Dissolution
  - 2.7.1.3 Comparison and Analyses of Results Across Studies
    - Table 2. Summary of Bioavailability (BA) Studies
    - Table 3. Statistical Summary of the Comparative BA Data
  - 2.7.1.4 Appendix
    - 2.7.4.1.3 Demographic and Other Characteristics of Study Population
      - Table 7. Demographic Profile of Subjects Completing the Bioequivalence Study
    - 2.7.4.2.1.1 Common Adverse Events
      - Table 8. Incidence of Adverse Events in Individual Studies
### MODULE 3
#### 3.2.S DRUG SUBSTANCE

<table>
<thead>
<tr>
<th>3.2.S.1</th>
<th>General Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2.S.1.1</td>
<td>Nomenclature</td>
</tr>
<tr>
<td>3.2.S.1.2</td>
<td>Structure</td>
</tr>
<tr>
<td>3.2.S.1.3</td>
<td>General Properties</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3.2.S.2</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2.S.2.1</td>
<td>Manufacturer(s) (This section includes contract manufacturers and testing labs)</td>
</tr>
<tr>
<td>Drug Substance (Active Pharmaceutical Ingredient)</td>
<td></td>
</tr>
<tr>
<td>1. Name and Full Address(es) of the Facility(ies)</td>
<td>yes</td>
</tr>
<tr>
<td>2. Function or Responsibility</td>
<td>yes</td>
</tr>
<tr>
<td>3. Type II DMF number for API</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>4. CFN or FEI numbers</td>
<td>(b) (4)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3.2.S.3</th>
<th>Characterization</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>3.2.S.4</th>
<th>Control of Drug Substance (Active Pharmaceutical Ingredient)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2.S.4.1</td>
<td>Specification</td>
</tr>
<tr>
<td>Testing specifications and data from drug substance manufacturer(s)</td>
<td>yes</td>
</tr>
<tr>
<td>3.2.S.4.2</td>
<td>Analytical Procedures</td>
</tr>
<tr>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>3.2.S.4.3</td>
<td>Validation of Analytical Procedures</td>
</tr>
<tr>
<td>1. Spectra and chromatograms for reference standards and test samples</td>
<td>yes</td>
</tr>
<tr>
<td>2. Samples-Statement of Availability and Identification of:</td>
<td></td>
</tr>
<tr>
<td>a. Drug Substance</td>
<td>yes</td>
</tr>
<tr>
<td>b. Same lot number(s)</td>
<td>yes</td>
</tr>
<tr>
<td>3.2.S.4.4</td>
<td>Batch Analysis</td>
</tr>
<tr>
<td>1. COA(s) specifications and test results from drug substance mfr(s)</td>
<td>yes</td>
</tr>
<tr>
<td>2. Applicant certificate of analysis</td>
<td>yes</td>
</tr>
<tr>
<td>3.2.S.4.5</td>
<td>Justification of Specification</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3.2.S.5</th>
<th>Reference Standards or Materials</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>3.2.S.6</th>
<th>Container Closure Systems</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>3.2.S.7</th>
<th>Stability</th>
</tr>
</thead>
</table>

Reference ID: 2904915
3.2.P.1 Description and Composition of the Drug Product

1. Unit composition

Composition

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>w/v %</th>
<th>w/w %</th>
<th>IIG limits per topical product</th>
<th>Purpose in formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flucinolone Acetate, USP</td>
<td>0.01 g</td>
<td>0.011</td>
<td>NA</td>
<td>Active ingredient</td>
</tr>
<tr>
<td>Isopropyl Alcohol, USP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peanut Oil, NF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oleth-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isopropyl Myristate, NF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Light Mineral Oil, NF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2 From IIG Table - amount in our product was qualified by controlled document with Martina Shimer

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>topical, oil</th>
<th>n.a.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isopropyl alcohol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peanut oil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oleth-2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Inactive ingredients and amounts are appropriate per IIG
Relevant INDs/NDAs/DMFs:

1) IND 33,448 (Derma-Smoothe FS for treatment of psoriasis of the scalp; submitted 7/27/89; HFD-540)
2) NDA 12-787 (Synalar Cream, fluocinolone acetonide, 0.025%; Corticosteroid responsive dermatoses; HFD-540; approved 2-15-63)
3) NDA 13-960 (Synalar Ointment, fluocinolone acetonide, 0.025%; Corticosteroid responsive dermatoses; HFD-540; approved 6-19-63)
4) NDA 15-296 (Synalar Solution, fluocinolone acetonide, 0.01%; Corticosteroid responsive dermatoses; HFD-540; approved 5-27-64)
5) NDA 16-161 (Synalar HP cream, fluocinolone acetonide; Corticosteroid responsive dermatoses; HFD-540; approved 7-25-67)
6) NDA 20-001 (FS shampoo, fluocinolone acetonide, 0.01%; Seborrheic dermatitis; HFD-540; 8-27-90)
7) NDA 21-112 (Tri-luma cream, fluocinolone acetonide, 0.01%, hydroquinone, 4%, tretinoin, 0.05%; Cutaneous melasma; HFD-540; 1-18-02)
8) DMF
9) DMF

Drug class: Corticosteroid

Indication: Atopic dermatitis and psoriasis of the scalp

Clinical formulation:

Each gram of Derma-Smoothe FS topical oil contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, refined peanut oil NF and fragrances.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refined peanut oil, NF</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>White Mineral Oil, USP</td>
<td></td>
</tr>
<tr>
<td>Oleth-2</td>
<td></td>
</tr>
<tr>
<td>Isopropyl Myristate, NF</td>
<td></td>
</tr>
<tr>
<td>Isopropyl Alcohol, NF</td>
<td></td>
</tr>
<tr>
<td>Cream Fragrance</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Balsam Pine Fragrance</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Fluocinolone Acetonide, USP</td>
<td>0.010</td>
</tr>
</tbody>
</table>

a – Refined peanut oil, NF has been heated at 475 °F for 15 minutes to denature possible peanut

From ANDA 91306
| 3.2.P.2 | **Pharmaceutical Development**  
Pharmaceutical Development Report  yes |
| --- | --- |

| 3.2.P.3 | **Manufacture**  
3.2.P.3.1 **Manufacture(s)** (Finished Dosage Manufacturer and Outside Contract Testing Laboratories)  
1. Name and Full Address(es) of the Facility(ies)  yes  
2. CGMP Certification:  yes  
3. Function or Responsibility  yes  
4. CFN or FEI numbers  |

| 3.2.P.3.2 | **Batch Formula**  yes |

| 3.2.P.3.3 | **Description of Manufacturing Process and Process Controls**  
1. Description of the Manufacturing Process  yes  
2. Master Production Batch Record(s) for largest intended production runs (no more than 10x pilot batch) with equipment specified  yes  
3. If sterile product: Aseptic fill / Terminal sterilization  
4. Reprocessing Statement  yes |

| 3.2.P.3.4 | **Controls of Critical Steps and Intermediates**  
3.2.P.3.5 **Process Validation and/or Evaluation**  
1. Microbiological sterilization validation  
2. Filter validation (if aseptic fill) |

| 3.2.P.4 | **Controls of Excipients (Inactive Ingredients)**  
Source of inactive ingredients identified  yes |

| 3.2.P.4.1 | **Specifications**  
1. Testing specifications (including identification and characterization)  yes  
2. Suppliers’ COA (specifications and test results)  yes |

| 3.2.P.4.2 | **Analytical Procedures**  
3.2.P.4.3 **Validation of Analytical Procedures**  
3.2.P.4.4 **Justification of Specifications**  
Applicant COA  yes |

Reference ID: 2904915
### 3.2.P DRUG PRODUCT

#### 3.2.P.5 Controls of Drug Product

<table>
<thead>
<tr>
<th>Specification(s)</th>
<th>yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analytical Procedures</td>
<td>yes</td>
</tr>
</tbody>
</table>

#### 3.2.P.5.1 Specification(s)
- yes

#### 3.2.P.5.2 Analytical Procedures
- yes

#### 3.2.P.5.3 Validation of Analytical Procedures
- Samples - Statement of Availability and Identification of:
  1. Finished Dosage Form  yes
  2. Same lot numbers  BB-ST-10001

#### 3.2.P.5.4 Batch Analysis
- Certificate of Analysis for Finished Dosage Form

#### 3.2.P.5.5 Characterization of Impurities

#### 3.2.P.5.6 Justification of Specifications

#### 3.2.P.7 Container Closure System

| Summary of Container/Closure System (if new resin, provide data) | yes |
| Components Specification and Test Data | yes |
| Packaging Configuration and Sizes | yes |
| Container/Closure Testing | yes |
| Source of supply and suppliers address | yes |

#### 3.2.P.8 Stability (Finished Dosage Form)

| Stability Protocol submitted | yes |
| Expiration Dating Period | 24 month |

#### 3.2.P.8.1 Stability (Finished Dosage Form)
- yes

#### 3.2.P.8.2 Post-approval Stability and Conclusion
- Post Approval Stability Protocol and Commitments yes

#### 3.2.P.8.3 Stability Data

| 3 month accelerated stability data | yes |
| Batch numbers on stability records the same as the test batch | yes |
### MODULE 3

**3.2.R Regional Information**

<table>
<thead>
<tr>
<th>3.2.R (Drug Substance)</th>
<th>3.2.R.1.S Executed Batch Records for drug substance (if available)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3.2.R.2.S Comparability Protocols</td>
</tr>
<tr>
<td></td>
<td>3.2.R.3.S Methods Validation Package</td>
</tr>
<tr>
<td></td>
<td>Methods Validation Package (3 copies) (Mult Copies N/A for E-Submissions)</td>
</tr>
<tr>
<td></td>
<td>(Required for Non-USP drugs)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3.2.R (Drug Product)</th>
<th>3.2.R.1.P.1 Executed Batch Records</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Copy of Executed Batch Record with Equipment Specified, including Packaging Records</td>
</tr>
<tr>
<td></td>
<td>(Packaging and Labeling Procedures)</td>
</tr>
<tr>
<td></td>
<td>Batch Reconciliation and Label Reconciliation</td>
</tr>
<tr>
<td></td>
<td>Theoretical Yield</td>
</tr>
<tr>
<td></td>
<td>Actual Yield</td>
</tr>
<tr>
<td></td>
<td>Packaged Yield</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3.2.R.1.P.2 Information on Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2.R.2.P Comparability Protocols</td>
</tr>
<tr>
<td>3.2.R.3.P Methods Validation Package</td>
</tr>
<tr>
<td>Methods Validation Package (3 copies) (Mult Copies N/A for E-Submissions)</td>
</tr>
<tr>
<td>(Required for Non-USP drugs)</td>
</tr>
</tbody>
</table>

### MODULE 5

**CLINICAL STUDY REPORTS**

<table>
<thead>
<tr>
<th>5.2</th>
<th>Tabular Listing of Clinical Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.3.1 (complete study data)</td>
<td>Bioavailability/Bioequivalence</td>
</tr>
<tr>
<td></td>
<td>1. Formulation data same?</td>
</tr>
<tr>
<td></td>
<td>a. Comparison of all Strengths (check proportionality of multiple strengths)</td>
</tr>
<tr>
<td></td>
<td>b. Parenterals, Ophthalmics, Otics and Topicals</td>
</tr>
<tr>
<td></td>
<td>per 21 CFR 314.94 (a)(9)(iii)-(v)</td>
</tr>
<tr>
<td></td>
<td>2. Lot Numbers of Products used in BE Study(ies):</td>
</tr>
<tr>
<td></td>
<td>3. Study Type: IN-VIVO PK STUDY(IES) (Continue with the appropriate study type box below)</td>
</tr>
</tbody>
</table>
### 5.3.1.2 Comparative BA/BE Study Reports
1. Study(ies) meets BE criteria (90% CI of 80-125, C max, AUC)
2. Summary Bioequivalence tables:
   - Table 10. Study Information
   - Table 12. Dropout Information
   - Table 13. Protocol Deviations

### 5.3.1.3 In Vitro-In-Vivo Correlation Study Reports
1. Summary Bioequivalence tables:
   - Table 11. Product Information
   - Table 16. Composition of Meal Used in Fed Bioequivalence Study

### 5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies
1. Summary Bioequivalence table:
   - Table 9. Reanalysis of Study Samples
   - Table 14. Summary of Standard Curve and QC Data for Bioequivalence Sample Analyses
   - Table 15. SOPs Dealing with Bioanalytical Repeats of Study Samples

### 5.3.7 Case Report Forms and Individual Patient Listing

### 5.4 Literature References

#### Possible Study Types:

<table>
<thead>
<tr>
<th>Study Type</th>
<th>YES/NO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IN-VIVO BE STUDY(IES) with PK ENDPOINTS</strong> (i.e., fasting/fed/sprinkle)</td>
<td>NA</td>
</tr>
<tr>
<td>1. Study(ies) meets BE criteria (90% CI of 80-125, C max, AUC)</td>
<td></td>
</tr>
<tr>
<td>2. EDR Email: Data Files Submitted:</td>
<td>NA</td>
</tr>
<tr>
<td>3. In-Vitro Dissolution:</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Type</th>
<th>YES/NO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IN-VIVO BE STUDY with CLINICAL ENDPOINTS</strong></td>
<td>NO</td>
</tr>
<tr>
<td>1. Properly defined BE endpoints (eval. by Clinical Team)</td>
<td></td>
</tr>
<tr>
<td>2. Summary results meet BE criteria: 90% CI of the proportional difference in success rate between test and reference must be within (-0.20, +0.20) for a binary/dichotomous endpoint. For a continuous endpoint, the test/reference ratio of the mean result must be within (0.80, 1.25).</td>
<td></td>
</tr>
<tr>
<td>3. Summary results indicate superiority of active treatments (test &amp; reference) over vehicle/placebo (p&lt;0.05) (eval. by Clinical Team)</td>
<td></td>
</tr>
<tr>
<td>4. EDR Email: Data Files Submitted</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Type</th>
<th>YES/NO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IN-VITRO BE STUDY(IES)</strong> (i.e., in vitro binding assays)</td>
<td>NO</td>
</tr>
<tr>
<td>1. Study(ies) meets BE criteria (90% CI of 80-125)</td>
<td></td>
</tr>
<tr>
<td>2. EDR Email: Data Files Submitted:</td>
<td></td>
</tr>
<tr>
<td>3. In-Vitro Dissolution:</td>
<td></td>
</tr>
</tbody>
</table>

Reference ID: 2904915
<table>
<thead>
<tr>
<th>Study Type</th>
<th>NASALLY ADMINISTERED DRUG PRODUCTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. <strong>Solutions</strong> (Q1/Q2 sameness):</td>
</tr>
<tr>
<td></td>
<td>a. In-Vitro Studies (Dose/Spray Content Uniformity, Droplet/Drug Particle Size Distrib., Spray Pattern, Plume Geometry, Priming &amp; Repriming)</td>
</tr>
<tr>
<td></td>
<td>2. <strong>Suspensions</strong> (Q1/Q2 sameness):</td>
</tr>
<tr>
<td></td>
<td>a. In-Vivo PK Study</td>
</tr>
<tr>
<td></td>
<td>1. Study(ies) meets BE Criteria (90% CI of 80-125, C max, AUC)</td>
</tr>
<tr>
<td></td>
<td>2. EDR Email: Data Files Submitted</td>
</tr>
<tr>
<td></td>
<td>b. In-Vivo BE Study with Clinical End Points</td>
</tr>
<tr>
<td></td>
<td>1. Properly defined BE endpoints (eval. by Clinical Team)</td>
</tr>
<tr>
<td></td>
<td>2. Summary results meet BE criteria (90% CI within +/- 20% of 80-125)</td>
</tr>
<tr>
<td></td>
<td>3. Summary results indicate superiority of active treatments (test &amp; reference) over vehicle/placebo (p&lt;0.05) (eval. by Clinical Team)</td>
</tr>
<tr>
<td></td>
<td>4. EDR Email: Data Files Submitted</td>
</tr>
<tr>
<td></td>
<td>c. In-Vitro Studies (Dose/Spray Content Uniformity, Droplet/Drug Particle Size Distrib., Spray Pattern, Plume Geometry, Priming &amp; Repriming)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Type</th>
<th>IN-VIVO BE STUDY(IES) with PD ENDPOINTS (e.g., topical corticosteroid vasoconstrictor studies)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Pilot Study (determination of ED50)</td>
</tr>
<tr>
<td></td>
<td>2. Pivotal Study (study meets BE criteria 90% CI of 80-125)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Type</th>
<th>TRANSDERMAL DELIVERY SYSTEMS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. In-Vivo PK Study</td>
</tr>
<tr>
<td></td>
<td>1. Study(ies) meet BE Criteria (90% CI of 80-125, C max, AUC)</td>
</tr>
<tr>
<td></td>
<td>2. In-Vitro Dissolution</td>
</tr>
<tr>
<td></td>
<td>3. EDR Email: Data Files Submitted</td>
</tr>
<tr>
<td></td>
<td>2. Adhesion Study</td>
</tr>
<tr>
<td></td>
<td>3. Skin Irritation/Sensitization Study</td>
</tr>
</tbody>
</table>

Updated 10/19/2009
<table>
<thead>
<tr>
<th>Reference ID</th>
<th>Yes/No</th>
<th>Name</th>
<th>Formulation</th>
<th>Concentration</th>
<th>Strength</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>N019452</td>
<td>Yes</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>OIL/DROPS, OTIC</td>
<td>0.01%</td>
<td>DERMOTIC</td>
<td>HILL DERMAC</td>
</tr>
<tr>
<td>N019452</td>
<td>Yes</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>OIL, TOPICAL</td>
<td>0.01%</td>
<td>DERMASMOOTHERFS</td>
<td>HILL DERMAC</td>
</tr>
<tr>
<td>N019452</td>
<td>Yes</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>OIL, TOPICAL</td>
<td>0.01%</td>
<td>DERMASMOOTHERFS</td>
<td>HILL DERMAC</td>
</tr>
<tr>
<td>A088168</td>
<td>AT</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>OINTMENT, TOPICAL</td>
<td>0.023%</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>FOUJERA</td>
</tr>
<tr>
<td>N019960</td>
<td>AT</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>OINTMENT, TOPICAL</td>
<td>0.025%</td>
<td>SYNALAR</td>
<td>MEDICIS</td>
</tr>
<tr>
<td>A040041</td>
<td>AT</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>OINTMENT, TOPICAL</td>
<td>0.025%</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>TARO</td>
</tr>
<tr>
<td>N020001</td>
<td>Yes</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>SHAMPOO, TOPICAL</td>
<td>0.01%</td>
<td>CAPEX</td>
<td>GALDERMA LABS LP</td>
</tr>
<tr>
<td>A088167</td>
<td>AT</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>SOLUTION, TOPICAL</td>
<td>0.01%</td>
<td>FLUCINOLONE ACETONIDE</td>
<td>FOUJERA</td>
</tr>
</tbody>
</table>
Search results from the "OB_Rx" table for query on "019452."

<table>
<thead>
<tr>
<th>Active Ingredient:</th>
<th>FLUCINOLONE ACETONIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage Form:Route:</td>
<td>OIL TOPICAL</td>
</tr>
<tr>
<td>Proprietary Name:</td>
<td>DERMA-SMOOTHE/PFS</td>
</tr>
<tr>
<td>Applicant:</td>
<td>HILL DERMAC</td>
</tr>
<tr>
<td>Strength:</td>
<td>0.01%</td>
</tr>
<tr>
<td>Application Number:</td>
<td>N019452</td>
</tr>
<tr>
<td>Product Number:</td>
<td>001</td>
</tr>
<tr>
<td>Approval Date:</td>
<td>Feb 3, 1998</td>
</tr>
<tr>
<td>Reference Listed Drug:</td>
<td>Yes</td>
</tr>
<tr>
<td>RX/OTC/DISCN:</td>
<td>RX</td>
</tr>
</tbody>
</table>

Patent and Exclusivity Info for this product: View

<table>
<thead>
<tr>
<th>Active Ingredient:</th>
<th>FLUCINOLONE ACETONIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage Form:Route:</td>
<td>OIL TOPICAL</td>
</tr>
<tr>
<td>Proprietary Name:</td>
<td>DERMA-SMOOTHE/PFS</td>
</tr>
<tr>
<td>Applicant:</td>
<td>HILL DERMAC</td>
</tr>
<tr>
<td>Strength:</td>
<td>0.01%</td>
</tr>
<tr>
<td>Application Number:</td>
<td>N019452</td>
</tr>
<tr>
<td>Product Number:</td>
<td>002</td>
</tr>
<tr>
<td>Approval Date:</td>
<td>Nov 9, 2005</td>
</tr>
<tr>
<td>Reference Listed Drug:</td>
<td>Yes</td>
</tr>
<tr>
<td>RX/OTC/DISCN:</td>
<td>RX</td>
</tr>
</tbody>
</table>

Reference ID: 2904915
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 019452 Product 001 in the OB_Rx list.

There are no unexpired patents for this product in the Orange Book Database.

Appl No  Prod No  Exclusivity Code  Exclusivity Expiration
N019452  001  NPP  Dec 12, 2010

View a list of all patent use codes
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

TIMOTHY G JETTON
02/14/2011

MARTIN H Shimer
02/16/2011
SciRegs International, Inc.
U.S. Agent for Identi Pharmaceuticals Inc.
Attention: C. Jeanne Taborsky
6333 Summercrest Drive
Columbia, MD 21045

Dear Madam:

We acknowledge the receipt of your abbreviated new drug application submitted pursuant to Section 505(j) of the Federal Food, Drug and Cosmetic Act.

Reference is also made to the telephone conversation dated January 3, 2010 and your correspondence dated January 10 and January 13, 2010.

NAME OF DRUG: Fluocinolone Acetonide Topical Oil (Scalp Oil), 0.01%

DATE OF APPLICATION: November 9, 2010

DATE (RECEIVED) ACCEPTABLE FOR FILING: November 10, 2010

We will correspond with you further after we have had the opportunity to review the application.

Please identify any communications concerning this application with the ANDA number shown above.

Should you have questions concerning this application, contact:

Trang Q. Tran
Project Manager
240-276-8518

Sincerely yours,

Wm Peter Rickman
Director
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research

Reference ID: 2904913
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARTIN H Shimer
02/16/2011
Signing for Wm Peter Rickman
RE: ANDA 201-759 Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)  
eCTD 0003 Gratuitous Amendment

Dear Sir/ Madam:

Pursuant to Code of Federal Regulations Title 21 § 314.96, SciRegs International, Inc., US Agent for Identi Pharmaceuticals, LLC, here within submits a gratuitous amendment to our abbreviated new drug application (ANDA) for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil). Reference is made to Identi’s Original Submission eCTD 0000, submitted November 9, 2010, and the telephone amendment eCTD 0002 submitted, January 10, 2011.

A typographical error was discovered in Module 2 Drug Product on page 14 of 29, in Table 11 In-process Bulk Testing, Assay results. In the column titled Top, the last value for the assay results was incorrectly transcribed as % rather than the correct result of %. Module 2 Drug Product has been corrected and is provided herein.

Identi is submitting a revised Module 2.7 Clinical Summary to correct a typographical error. The product is a topical solution and contains the same active and inactive ingredients in the same concentration as the reference listed drug product.

This completes our submission. This ANDA is filed in eCTD format. A Letter of Non-Repudiation for SciRegs International Inc. has been submitted to the Agency under separate cover dated, February 1, 2008. Please contact C. Jeanne Taborsky, SciRegs International Inc. at phone (410) 309-3145; fax (410) 309-6145, if you have any questions concerning this submission.

Sincerely yours,

C. Jeanne Taborsky,
US Regulatory Agent
SciRegs International Inc.
RE: ANDA 201-759 Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)  
eCTD 0001 Gratuitous Amendment

Dear Sir/ Madam:

Pursuant to Code of Federal Regulations Title 21 § 314.96, SciRegs International, Inc., US Agent for Identi Pharmaceuticals, LLC, here within submits a gratuitous amendment to our abbreviated new drug application (ANDA) for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil). Reference is made to Identi’s Original Submission eCTD 0000, submitted November 9, 2010.

was provided as a testing facility for the drug substance and drug product release and stability for the test batch in the original submission. was approved for this testing in the ANDA. Amneal is in the process of completing the methods transfer validation. Identi will continue using for drug substance and drug product release and stability testing until the method transfer validation has been completed at Amneal Pharmaceuticals. A revised stability protocol has been provided in Module 3 Section 3.2.P.8.1.

Please refer to the original submission Section 1.3.3 Debarment for the debarment certification and to Section 3.2.P.3.1 for the CGMP certification. These certifications were submitted in the original ANDA application eCTD 0000 dated, November 9, 2010. We note and acknowledge that all facilities referenced in our ANDA should be in compliance with cGMP at the time of approval. has already been inspected in conjunction with ANDA 91-306 Fluocinolone Acetonide Ointment (Ear Drops) in The inspection result was satisfactory.

This completes our submission. This ANDA is filed in eCTD format. A Letter of Non-Repudiation for SciRegs International Inc. has been submitted to the Agency under separate cover dated, February 1, 2008. Please contact C. Jeanne Taborsky, SciRegs International Inc. at phone (410) 309-3145; fax (410) 309-6145, if you have any questions concerning this submission.

Sincerely yours,

C. Jeanne Taborsky,
US Regulatory Agent
SciRegs International Inc.
CLINICAL REVIEW TEAM CHECKLIST FOR GENERIC ANDA
FOR APPLICATION COMPLETENESS

ANDA# 201759  FIRM NAME__Identi Pharmaceuticals, LLC__________

DRUG NAME __ Fluocinolone Acetonide Topical Oil, 0.01%_____________________

DOSAGE FORM __ topical oil (Scalp Oil)_____________________________________

REFERENCE LISTED DRUG (RLD) _Derma-Smoother/FS® (flucinolone acetonide) Topical oil
(for scalp use), 0.01%, NDA 019452___________

Requested by: _Washington, Edward___________________ Date: _11/16/10__________
Regulatory Support Team, (HFD-615)

Summary of Findings by Clinical Review Team

<table>
<thead>
<tr>
<th>Study meets statutory requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study does NOT meet statutory requirements</td>
</tr>
<tr>
<td><strong>Reason:</strong></td>
</tr>
<tr>
<td>X Waiver meets statutory requirements</td>
</tr>
<tr>
<td><strong>See Comments to be conveyed to the sponsor for details.</strong></td>
</tr>
<tr>
<td>Waiver does NOT meet statutory requirements</td>
</tr>
</tbody>
</table>

RECOMMENDATION: _X__COMPLETE  ___INCOMPLETE

Reviewed by:

__________________________________     Date: ____________________________
Reviewer
Carol Y. Kim, Pharm.D.
Clinical Reviewer

__________________________________     Date: ____________________________
Dena R. Hixon, M.D.
Associate Director for Medical Affairs

Reference ID: 2872055
<table>
<thead>
<tr>
<th>Item Verified:</th>
<th>YES</th>
<th>NO</th>
<th>Required Amount</th>
<th>Amount Sent</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composition</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>See comments below.</td>
</tr>
<tr>
<td>Waiver requests for other</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>See comments below.</td>
</tr>
<tr>
<td>strengths / supporting data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comments **NOT** to be conveyed to the sponsor:

Although Derma-Smoother Body Oil and Derma-Smoother Scalp oil are approved in a single NDA 019452, the FDA considers that they are two separate products with unique labeling. Derma-Smoother Body oil is indicated for atopic dermatitis. Derma-Smoother Scalp oil is indicated for scalp psoriasis and is packaged with a shower cap. Each drug product is identified with its own NDC number and each serves as a unique RLD.¹

The sponsor requests a waiver of the bioequivalence study requirement for their scalp oil product based on the conditions of 21 CFR 320.22 (b) (3) as follows:

1. Identi’s product is a non-aqueous solution for application to the skin.
2. It contains the same active and inactive ingredients in the same concentration as the reference listed drug product with the exception of the trace amounts of perfumes in the RLD.

A waiver of a bioequivalence study was granted (Clinical Review dated 8/31/10) for this same sponsor’s ANDA 091306 Fluocinolone Acetonide 0.01% Oil Ear Drop which contains identical active and inactive ingredients as their proposed fluocinolone acetonide 0.01% scalp oil. The Division of Dermatology and Dental Products determined that the omission of the two fragrance components in ANDA 091306 (ear drop) would not affect the safety or efficacy of the product.

The following tables show the formulation of the proposed product, which is the same as the formulation for the approved ear drops.

---
¹ Citizen Petition Docket no. FDA-2004-P-0215, page 11.
**Reviewer's Comment:** The sponsor states that the active ingredient manufacturer, formulation, raw material sources, specifications, testing controls and test methods for the finished products are the same for their ear drops (ANDA 091306), body oil (ANDA 201764), and scalp oil (current submission). The sponsor also states that they are using peanut oil from the same source as the RLD.

Comments to be conveyed to the sponsor

Your application is acceptable to be received as an ANDA.

Please correct the following in the submission:

1. Module 2 section 2.7 Clinical Summary (bioequivalence): Third paragraph stated that your product is an otic solution.
2. Module 1 section 1.12.12 comparison: Generic vs. Reference Listed Drug Product: Under conditions of use, your product was written for “chronic eczematous external otitis”

Reference ID: 2872055
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CAROL Y KIM  
12/03/2010

DENA R HIXON  
12/03/2010

I concur.
MEMORANDUM
DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE : November 15, 2010

TO : Director
Division of Bioequivalence (HFD-650)

FROM : Chief, Regulatory Support Branch
Office of Generic Drugs (HFD-615)

SUBJECT: Examination of the bioequivalence study submitted with an ANDA 201759 for Fluocinolone Acetonide, 0.01% Topical Oil (Scalp Oil) to determine if the application is substantially complete for filing.

Identi Pharmaceuticals Inc. has submitted ANDA 201759 for Fluocinolone Acetonide, 0.01% Topical Oil (Scalp Oil). In order to accept an ANDA the Agency must formally review and make a determination that the application is substantially complete. Included in this review is a determination that the bioequivalence study is complete, and could establish that the product is bioequivalent.

Please evaluate whether the request for study submitted by Identi Pharmaceuticals Inc. on November 9, 2010 for its Fluocinolone Acetonide product satisfies the statutory requirements of "completeness" so that the ANDA may be filed.

A "complete" bioavailability or bioequivalence study is defined as one that conforms with an appropriate FDA guidance or is reasonable in design and purports to demonstrate that the proposed drug is bioequivalent to the "listed drug".

Reference ID: 2864295
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

EDA E HOWARD
11/16/2010

Reference ID: 2864295
Office of Generic Drugs  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Document Control Room  
7620 Standish Place  
Rockville, MD 20855-2773

RE: ANDA 201-759 Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)  
eCTD 0000 Original Submission

Request for Expedited Review

Dear Sir/Madam:

Pursuant to Section 505 (j) of the Federal Food, Drug, and Cosmetic Act, SciRegs International, Inc., US Agent for Identi Pharmaceuticals, LLC, here within submits an abbreviated new drug application (ANDA) for Fluocinolone Acetonide 0.01% Topical Oil (scalp oil). A copy of our letter of Appointment is provided in Module 1 Section 1.4.1 References. Reference is made to our sister ANDA 091-306 Fluocinolone Acetonide 0.01% (Ear Drops) and FDA response, dated March 25, 2009, to the citizens petition filed by Hill Dermaceuticals Inc., Docket Number FDA-2004-P-0215.

This application references NDA 019452 Derma-Smooth/FS® Fluocinolone Acetonide 0.01% Topical Oil, listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), and manufactured by Hill Dermaceuticals, Inc. While the single NDA referenced above currently provides for three products, ear drops, body oil, and scalp oil, we were instructed by OGD to file separate ANDAs for these products since the labeling, packaging, indications and routes of administration are different. Please be advised that the active ingredient manufacturer, formation, raw material sources, specifications, testing and the controls and the test methods for the finished products are the same for all three of our submissions. ANDA 091-306 Fluocinolone Acetonide Oil 0.01% (Ear Drops) has already been subject to the FDA OGD review process.

The dosage form, route of administration, active ingredient, potency, and labeling (with the exception of brand name, logo, manufacturer, and NDC number) for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) are the same as those for Derma-Smoothe/FS® Fluocinolone Acetonide 0.01% Topical Oil. An electronic copy of the innovator labeling is provided in Module 1 Section 1.14.3.2 Approved labeling text for RLD and Section 1.14.3.3 Labeling Text, proposed labeling for Identi’s product is provided in Module 1 Section 1.14.1.1 Draft Labeling and Section 1.14.1.3 Draft Labeling Text, and the side-by-sides are provided in Module 1 Section 1.14.1.2 Annotated Draft Labeling Text and Section 1.14.3.1 Annotated Comparison with Listed Drug.

(b) (4)

is the manufacturer of the Active Pharmaceutical Ingredient (API), Fluocinolone Acetonide, USP, used in Identi’s drug product. (b) (4)
facility is responsible for manufacturing, testing, and stability of the API. This API manufacturing facility was last inspected by the US FDA. The API site is ready for inspection. Information on these facilities is provided in Module 3 Section 3.2.S.2 Manufacture. The sites are ready for inspection. Information on this manufacturer and the drug substance drug master file were reviewed for sister ANDA 091-306 Fluocinolone Acetonide Oil 0.01% (Ear Drops) and found acceptable.

The drug substance is the subject of an USP monograph; therefore, methods validation was not required for the drug substance assay and was provided only for the drug substance related substances, residual solvents and the drug product. The Firm commits to provide any additional information and resolve any issues identified in the methods validation process after approval.

The drug product manufactured in support of this ANDA submission was and will be manufactured at the contract manufacturing facility, Amneal Pharmaceuticals located in Branchburg, NJ. This facility is also responsible for receiving raw materials and components, manufacturing, and packaging the drug product. The facility is FDA registered and meets all applicable cGMPs. The facility was last inspected by US FDA, in July 2010, and was classified as acceptable. The facility is ready for inspection. Additional information regarding this facility is located in Module 3 Section 3.2.P.3.1 Manufacture.

The entire test batch was packaged in bottles with specially designed continuous thread closures fitted with liners. To match the RLD packaging configuration, the container closure system includes a dispensing closure. This closure is provided in the carton and is applied by the consumer at the time of use. Information on the container/closure system is provided in Module 3 Section 3.2.P.7 Container Closure System and Module 3.2.R.1.P.2 Information on Components. The components were tested in conformance with USP <661> Containers. Additional migration and compatibility studies were conducted on the components including the dispensing cap. The closures used for this submission are the same ones used for the ear drop product. The 4-ounce bottles are manufactured by the same company and of
the same materials of construction as the 1-ounce bottles used for sister ANDA 091-306 Fluocinolone Acetonide Oil 0.01% (Ear Drops).

The same test method and validation information submitted and reviewed for ANDA 091306 Fluocinolone Acetonide 0.01% (Ear Drops) and found acceptable is used for this ANDA. FDA verification of the analytical methods is pending.

Stability studies were conducted under a stability protocol that is in conformance with the ICH Stability Guidelines. The drug product is to be stored upright at USP MKT 25°C and shipped USP refrigerated. Identi requests approval of a two-year expiration dating for these products as supported by one, two, and three month’s accelerated stability data (40°C ± 2°C / 75% ± 5% RH), and controlled room temperature conditions (25°C ± 2°C / 60% ± 5% RH) to date. A copy of the forced degradation studies is also provided in Module 3 Section 3.2.P.8.3 Stability Data to Date.

Identi is requesting a waiver from in-vivo bioequivalence studies based upon the fact that the formulation for our product is the same (with the exception of the fragrance) as the innovator product. The waiver is located in Module 1 Section 1.12.15 Request for Waiver. Regulations provide for FDA to waive the submission requirement for evidence of in vivo bioequivalence when the drug product is (l) "a solution for application to the skin," (2) "contains an active drug ingredient in the same concentration and dosage form" as the RLD, and (3) "contains no inactive ingredient or other change in formulation" from the RLD "that may significantly affect systemic or local availability for products intended to act locally." Identi has met the requirements, by reverse engineering the formulation to match the innovator. Additionally, the innovator contended in their petition, that the Peanut Oil was critical to the delivery of the product and Identi believes that it is using Peanut Oil from the same source. The request for waiver of bioequivalence testing has been granted for the ear drop product. Please also reference Module 5 Section 5.3.1.3 Bioequivalence.

This completes our submission. This ANDA is filed in eCTD format. As requested by the agency, WORD versions of Module 2 and labeling are provided in this eCTD submission. The Letter of Non-Repudiation for Identi Pharmaceuticals LLC has been submitted to the Agency under separate cover, dated August 17, 2010. The Letter of Non-Repudiation for SciRegs International Inc. has been submitted to the Agency under separate cover, dated February 1, 2008. Please contact C. Jeanne Taborsky, SciRegs International Inc. at phone (410) 309-3145; fax (410) 309-6145, if you have any questions concerning this submission.

Sincerely yours,

C. Jeanne Taborsky
US Regulatory Agent
SciRegs International Inc.
Office of Generic Drugs  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Document Control Room  
7620 Standish Place  
Rockville, MD 20855-2773

January 10, 2010

RE: ANDA 201-759 Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)  
eCTD 0002 Telephone Amendment

Dear Sir/ Madam:

Pursuant to Code of Federal Regulations Title 21 § 314.96, SciRegs International, Inc., US Agent for Identi Pharmaceuticals, LLC, here within submits a telephone amendment to our abbreviated new drug application (ANDA) for Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil). Reference is made to Identi’s Original Submission eCTD 0000, submitted November 9, 2010, and the telephone conversation with FDA reviewer Tim Jetton on January 3, 2011.

The following requests were made

1. **Please provide Module 2 documents in WORD version.**

   As requested, the WORD versions of the documents for Module 2 from the original submission have been provided herein. Please refer to the following sections: Module 2 Introduction, Module 2 Drug Substance, Module 2 Drug Product and Module 2 Clinical Summary.

2. **The CGMP Certification for the drug substance manufacturer is not adequate. Please provide a certification stating compliance with 21 CFR 210 and 211.**

   A CGMP certification for [insert name of manufacturer], the drug substance manufacturer, has been revised to include a statement of compliance with 21 CFR 210 and 211. The revised certificate is provided in Module 3 Section 3.2.S.2.1 Manufacturer.

3. **Please provide the spectra and chromatograms for the testing of the drug substance.**

   The spectra and chromatogram for the drug substance were inadvertently omitted from the original submission eCTD 0000, dated November 9, 2010. The spectra and chromatogram for the testing of the drug substance is provided in Module 3 Section 3.2.S.4.4 Batch Analysis.
4. Please provide the certificate of analysis for the drug product with the Lot Number listed on all pages.

The certificates of analysis for the drug product have been revised to list the batch lot number on all pages. The lot numbers were inadvertently omitted on the versions submitted in the original submission. There have been no changes to the data on the certificates of analysis. The revised certificates of analysis are provided in Module 3 Section 3.2 P 5.4 Batch Analysis.

This completes our submission. This ANDA is filed in eCTD format. A Letter of Non-Repudiation for SciRegs International Inc. has been submitted to the Agency under separate cover dated, February 1, 2008. Please contact C. Jeanne Taborsky, SciRegs International Inc. at phone (410) 309-3145; fax (410) 309-6145, if you have any questions concerning this submission.

Sincerely yours,

C. Jeanne Taborsky,
US Regulatory Agent
SciRegs International Inc.